<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>GRADO: L'arte di giudicare le prove</title>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Cormorant+Garamond:ital,wght@0,400;0,600;0,700;1,400;1,600&amp;family=Source+Sans+Pro:wght@300;400;600;700&amp;display=swap" rel="stylesheet"/>
<style>
    :root {
      --navy: #1E2761;
      --deep-navy: #141B3D;
      --gold: #D4AF37;
      --cream: #FAF8F5;
      --light-cream: #FFFFFF;
      --text: #2D3748;
      --light-text: #718096;
      --red: #C53030;
      --green: #22c55e;
      --teal: #0f766e;
      --purple: #7c3aed;
      --orange: #f59e0b;
      --transition: 0.5s cubic-bezier(0.4, 0, 0.2, 1);
    }

    * { margin: 0; padding: 0; box-sizing: border-box; }
    html, body {
      height: 100%;
      font-family: 'Source Sans Pro', sans-serif;
      background: var(--deep-navy);
      color: var(--cream);
    }

    .course-container { display: flex; height: 100vh; overflow: hidden; }

    /* Skip Link for Accessibility */
    .skip-link {
      position: absolute;
      top: -40px;
      left: 0;
      background: var(--gold);
      color: var(--navy);
      padding: 8px 16px;
      z-index: 10000;
      text-decoration: none;
      font-weight: 600;
    }
    .skip-link:focus { top: 0; }

    /* ====== SIDEBAR ====== */
    .sidebar {
      width: 300px;
      background: linear-gradient(180deg, var(--deep-navy) 0%, #0a0f1a 100%);
      border-right: 1px solid rgba(212,175,55,0.2);
      display: flex;
      flex-direction: column;
      flex-shrink: 0;
    }

    .sidebar-header {
      padding: 1.25rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      text-align: center;
    }
    .sidebar-header h1 {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: 1.3rem;
      font-weight: 700;
      color: var(--gold);
    }
    .sidebar-header p {
      font-size: 0.75rem;
      color: rgba(255,255,255,0.6);
    }

    /* Gamification Stats Panel */
    .stats-panel {
      padding: 1rem;
      background: rgba(212,175,55,0.1);
      border-bottom: 1px solid rgba(212,175,55,0.2);
    }
    .level-display {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .level-badge {
      width: 48px;
      height: 48px;
      background: linear-gradient(135deg, var(--gold), #f0c040);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.5rem;
      box-shadow: 0 2px 8px rgba(212,175,55,0.4);
    }
    .level-info { flex: 1; }
    .level-title { font-weight: 700; font-size: 0.9rem; color: var(--gold); }
    .level-subtitle { font-size: 0.7rem; color: rgba(255,255,255,0.6); }
    .xp-bar {
      height: 8px;
      background: rgba(255,255,255,0.1);
      border-radius: 4px;
      overflow: hidden;
      margin-top: 0.5rem;
    }
    .xp-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      border-radius: 4px;
      transition: width 0.5s ease;
    }
    .xp-text {
      font-size: 0.65rem;
      color: rgba(255,255,255,0.5);
      text-align: right;
      margin-top: 0.25rem;
    }
    .quick-stats {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 0.5rem;
      margin-top: 0.75rem;
    }
    .quick-stat {
      background: rgba(0,0,0,0.2);
      padding: 0.5rem;
      border-radius: 6px;
      text-align: center;
    }
    .quick-stat-value {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--gold);
    }
    .quick-stat-label {
      font-size: 0.6rem;
      color: rgba(255,255,255,0.5);
    }

    /* Course Progress */
    .course-progress {
      padding: 0.75rem 1rem;
      border-bottom: 1px solid rgba(212,175,55,0.2);
      background: rgba(0,0,0,0.2);
    }
    .course-progress-label {
      display: flex;
      justify-content: space-between;
      font-size: 0.7rem;
      color: rgba(255,255,255,0.6);
      margin-bottom: 0.35rem;
    }
    .course-progress-bar {
      height: 6px;
      background: rgba(255,255,255,0.1);
      border-radius: 3px;
      overflow: hidden;
    }
    .course-progress-fill {
      height: 100%;
      background: linear-gradient(90deg, var(--green), #22d3ee);
      border-radius: 3px;
      transition: width 0.5s ease;
    }

    .module-list { flex: 1; overflow-y: auto; padding: 0.5rem 0; }
    .module-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 1rem;
      cursor: pointer;
      transition: all 0.2s;
      border-left: 3px solid transparent;
    }
    .module-item:hover { background: rgba(212,175,55,0.1); }
    .module-item.active { background: rgba(212,175,55,0.15); border-left-color: var(--gold); }
    .module-item.completed .module-number { background: var(--green); color: white; }
    .module-item.locked { opacity: 0.5; cursor: not-allowed; }
    .module-number {
      width: 26px;
      height: 26px;
      border-radius: 50%;
      background: rgba(255,255,255,0.1);
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.7rem;
      font-weight: 700;
      flex-shrink: 0;
    }
    .module-item.active .module-number { background: var(--gold); color: var(--navy); }
    .module-info { flex: 1; min-width: 0; }
    .module-title { font-size: 0.8rem; font-weight: 600; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; }
    .module-subtitle { font-size: 0.65rem; color: rgba(255,255,255,0.5); }
    .module-xp { font-size: 0.6rem; color: var(--gold); }
    .module-time { font-size: 0.55rem; color: rgba(255,255,255,0.4); display: flex; align-items: center; gap: 0.25rem; margin-top: 0.15rem; }

    /* Badges Panel */
    .badges-panel {
      padding: 1rem;
      border-top: 1px solid rgba(212,175,55,0.2);
    }
    .badges-title { font-size: 0.75rem; font-weight: 600; color: var(--gold); margin-bottom: 0.5rem; }
    .badges-grid { display: flex; flex-wrap: wrap; gap: 0.35rem; }
    .badge-item {
      width: 32px;
      height: 32px;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.1);
      border-radius: 6px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 0.9rem;
      opacity: 0.3;
      transition: all 0.3s;
      cursor: help;
      position: relative;
      padding: 0;
      color: inherit;
    }
    .badge-item.earned { opacity: 1; background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .badge-item:hover::after {
      content: attr(title);
      position: absolute;
      bottom: 100%;
      left: 50%;
      transform: translateX(-50%);
      background: var(--navy);
      color: white;
      padding: 0.25rem 0.5rem;
      border-radius: 4px;
      font-size: 0.6rem;
      white-space: nowrap;
      z-index: 100;
    }

    /* ====== MAIN CONTENT ====== */
    .main-content { flex: 1; display: flex; flex-direction: column; overflow: hidden; }
    .content-header {
      padding: 0.75rem 1.5rem;
      background: rgba(0,0,0,0.3);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      display: flex;
      align-items: center;
      justify-content: space-between;
    }
    .breadcrumb { font-size: 0.85rem; color: rgba(255,255,255,0.6); }
    .breadcrumb span { color: var(--gold); }
    .header-actions { display: flex; gap: 0.5rem; align-items: center; }
    .streak-display {
      display: flex;
      align-items: center;
      gap: 0.35rem;
      background: rgba(239,68,68,0.2);
      border: 1px solid rgba(239,68,68,0.4);
      padding: 0.35rem 0.75rem;
      border-radius: 20px;
      font-size: 0.8rem;
    }
    .streak-display.active { background: rgba(249,115,22,0.2); border-color: var(--orange); }
    .streak-flame { font-size: 1rem; }
    .streak-count { font-weight: 700; color: var(--orange); }

    .btn {
      padding: 0.5rem 1rem;
      border: 1px solid rgba(212,175,55,0.3);
      border-radius: 6px;
      background: rgba(255,255,255,0.05);
      color: var(--cream);
      font-size: 0.8rem;
      cursor: pointer;
      transition: all 0.2s;
    }
    .btn:hover { background: rgba(212,175,55,0.2); border-color: var(--gold); }
    .btn.primary { background: var(--gold); color: var(--navy); border-color: var(--gold); font-weight: 600; }

    .content-body { flex: 1; overflow: hidden; display: flex; }

    /* ====== SLIDES ====== */
    .slides-container { flex: 1; position: relative; overflow: hidden; }
    .module-slides { display: none; width: 100%; height: 100%; }
    .module-slides.active { display: block; }

    .slide {
      position: absolute;
      top: 0; left: 0;
      width: 100%; height: 100%;
      display: flex;
      flex-direction: column;
      justify-content: flex-start;
      align-items: center;
      padding: 2rem 2rem 4rem;
      opacity: 0;
      visibility: hidden;
      transition: opacity var(--transition), visibility var(--transition);
      overflow-y: auto;
    }
    .slide.active { opacity: 1; visibility: visible; }
    .slide.dark { background: var(--deep-navy); }
    .slide.light { background: var(--cream); color: var(--text); }
    .slide.black { background: #000; }
    .slide.red-bg { background: linear-gradient(135deg, #7f1d1d, #450a0a); }
    .slide.green-bg { background: linear-gradient(135deg, #14532d, #052e16); }
    .slide.purple-bg { background: linear-gradient(135deg, #4c1d95, #2e1065); }
    .slide.orange-bg { background: linear-gradient(135deg, #9a3412, #431407); }

    .slide-progress-bar {
      position: absolute;
      top: 0;
      left: 0;
      height: 3px;
      background: linear-gradient(90deg, var(--gold), var(--orange));
      transition: width 0.3s ease;
      z-index: 50;
    }

    .serif { font-family: 'Cormorant Garamond', Georgia, serif; }
    .title {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.8rem, 4vw, 3rem);
      font-weight: 700;
      margin-bottom: 1rem;
      line-height: 1.2;
      text-align: center;
    }
    .title.gold { color: var(--gold); }
    .title.navy { color: var(--navy); }
    .subtitle {
      font-size: clamp(0.9rem, 2vw, 1.3rem);
      color: rgba(255,255,255,0.7);
      margin-bottom: 1.5rem;
      text-align: center;
    }
    .slide.light .subtitle { color: var(--light-text); }

    .big-number {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(4rem, 12vw, 8rem);
      font-weight: 700;
      line-height: 1;
    }
    .big-number.gold { color: var(--gold); }
    .big-number.red { color: var(--red); }

    .refrain {
      font-family: 'Cormorant Garamond', Georgia, serif;
      font-size: clamp(1.3rem, 3vw, 2rem);
      font-style: italic;
      color: var(--gold);
      text-align: center;
      max-width: 700px;
    }

    .content { display: flex; flex-direction: column; align-items: center; width: 100%; max-width: 850px; }

    /* Cards */
    .card {
      background: var(--light-cream);
      border: 1px solid var(--gold);
      padding: 1.25rem 1.5rem;
      margin: 0.5rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 8px;
    }
    .card.navy-bg { background: var(--navy); color: var(--cream); }
    .card.red-border { border: 2px solid var(--red); }
    .card.green-border { border: 2px solid var(--green); }
    .card-label {
      font-size: 0.7rem;
      font-weight: 700;
      color: var(--gold);
      letter-spacing: 0.05em;
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .card-text { font-size: 0.95rem; line-height: 1.6; }
    .card.navy-bg .card-text { color: var(--cream); }

    /* Story box */
    .story-box {
      background: linear-gradient(135deg, rgba(197,48,48,0.15), rgba(30,39,97,0.2));
      border-left: 4px solid var(--red);
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 750px;
      width: 100%;
      border-radius: 0 8px 8px 0;
    }
    .story-box.success { background: linear-gradient(135deg, rgba(34,197,94,0.15), rgba(30,39,97,0.2)); border-left-color: var(--green); }
    .story-box.warning { background: linear-gradient(135deg, rgba(245,158,11,0.15), rgba(30,39,97,0.2)); border-left-color: var(--orange); }
    .story-label {
      font-size: 0.7rem;
      font-weight: 700;
      letter-spacing: 0.1em;
      color: var(--red);
      margin-bottom: 0.4rem;
      text-transform: uppercase;
    }
    .story-box.success .story-label { color: var(--green); }
    .story-box.warning .story-label { color: var(--orange); }
    .story-text { font-size: 0.95rem; line-height: 1.6; }

    /* Epic Story Box */
    .story-box.epic {
      background: linear-gradient(135deg, rgba(20,27,61,0.95), rgba(0,0,0,0.9));
      border-left: 4px solid var(--gold);
      border-top: 1px solid rgba(212,175,55,0.3);
      border-right: 1px solid rgba(212,175,55,0.2);
      border-bottom: 1px solid rgba(212,175,55,0.2);
      padding: 1.5rem;
      position: relative;
    }
    .story-box.epic::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, var(--gold), transparent);
    }
    .story-box.epic .story-label { color: var(--gold); font-size: 0.65rem; letter-spacing: 0.15em; }
    .story-box.epic .story-text { font-family: 'Cormorant Garamond', Georgia, serif; font-size: 1.05rem; line-height: 1.7; }

    /* GRADE Certainty Colors */
    .grade-high { background: linear-gradient(135deg, rgba(34,197,94,0.2), rgba(30,39,97,0.2)); border-color: var(--green); }
    .grade-moderate { background: linear-gradient(135deg, rgba(59,130,246,0.2), rgba(30,39,97,0.2)); border-color: #3b82f6; }
    .grade-low { background: linear-gradient(135deg, rgba(245,158,11,0.2), rgba(30,39,97,0.2)); border-color: var(--orange); }
    .grade-very-low { background: linear-gradient(135deg, rgba(197,48,48,0.2), rgba(30,39,97,0.2)); border-color: var(--red); }

    .grade-badge {
      display: inline-block;
      padding: 0.25rem 0.75rem;
      border-radius: 4px;
      font-size: 0.75rem;
      font-weight: 700;
      text-transform: uppercase;
      letter-spacing: 0.05em;
    }
    .grade-badge.high { background: var(--green); color: white; }
    .grade-badge.moderate { background: #3b82f6; color: white; }
    .grade-badge.low { background: var(--orange); color: white; }
    .grade-badge.very-low { background: var(--red); color: white; }

    /* Stats */
    .stats-grid {
      display: flex;
      gap: 0.75rem;
      margin: 1rem 0;
      flex-wrap: wrap;
      justify-content: center;
    }
    .stat-box {
      background: var(--navy);
      color: var(--cream);
      padding: 1rem 1.25rem;
      text-align: center;
      min-width: 120px;
      border-radius: 8px;
    }
    .stat-box.light { background: var(--light-cream); color: var(--navy); border: 1px solid var(--gold); }
    .stat-value {
      font-family: 'Cormorant Garamond', serif;
      font-size: clamp(1.3rem, 2.5vw, 2rem);
      font-weight: 700;
    }
    .stat-value.gold { color: var(--gold); }
    .stat-value.red { color: var(--red); }
    .stat-value.green { color: var(--green); }
    .stat-label { font-size: 0.75rem; opacity: 0.8; margin-top: 0.2rem; }

    /* Timeline */
    .timeline { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .timeline-item {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border-left: 4px solid var(--gold);
    }
    .timeline-days { font-weight: 700; font-size: 0.8rem; min-width: 70px; color: var(--gold); }
    .timeline-content { flex: 1; }
    .timeline-title { font-weight: 600; font-size: 0.9rem; }
    .timeline-desc { font-size: 0.75rem; opacity: 0.7; }

    /* Checklist */
    .checklist { display: flex; flex-direction: column; gap: 0.4rem; width: 100%; max-width: 650px; }
    .checklist-item {
      display: flex;
      align-items: flex-start;
      gap: 0.6rem;
      padding: 0.6rem 0.75rem;
      background: rgba(255,255,255,0.05);
      border-radius: 6px;
      border: 1px solid rgba(255,255,255,0.1);
    }
    .check-icon {
      width: 22px;
      height: 22px;
      background: var(--gold);
      color: var(--navy);
      border-radius: 4px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.75rem;
      flex-shrink: 0;
    }
    .checklist-text { font-size: 0.9rem; line-height: 1.4; }

    /* Lessons */
    .lesson-item { display: flex; align-items: flex-start; gap: 0.75rem; margin: 0.5rem 0; max-width: 700px; }
    .lesson-number {
      background: var(--gold);
      color: var(--navy);
      width: 28px;
      height: 28px;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.85rem;
      flex-shrink: 0;
    }
    .lesson-content h4 { font-size: 1rem; font-weight: 700; margin-bottom: 0.2rem; }
    .lesson-content p { font-size: 0.85rem; opacity: 0.8; }

    /* ====== DECISION TREE ====== */
    .decision-tree {
      width: 100%;
      max-width: 700px;
      background: linear-gradient(135deg, rgba(124,58,237,0.15), rgba(30,39,97,0.25));
      border: 2px solid var(--purple);
      border-radius: 12px;
      padding: 1.5rem;
      margin: 0.75rem 0;
    }
    .decision-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 1rem;
    }
    .decision-icon {
      width: 40px;
      height: 40px;
      background: var(--purple);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.25rem;
    }
    .decision-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      font-weight: 700;
    }
    .decision-xp {
      margin-left: auto;
      background: rgba(212,175,55,0.2);
      padding: 0.25rem 0.75rem;
      border-radius: 12px;
      font-size: 0.75rem;
      color: var(--gold);
      font-weight: 600;
    }
    .decision-scenario {
      background: rgba(0,0,0,0.2);
      padding: 1rem;
      border-radius: 8px;
      margin-bottom: 1rem;
      font-size: 0.95rem;
      line-height: 1.6;
    }
    .decision-question {
      font-weight: 600;
      color: var(--gold);
      margin-bottom: 0.75rem;
      font-size: 1rem;
    }
    .decision-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .decision-option {
      display: flex;
      align-items: flex-start;
      gap: 0.75rem;
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.15);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
    }
    .decision-option:hover { background: rgba(124,58,237,0.2); border-color: var(--purple); }
    .decision-option.selected { background: rgba(124,58,237,0.3); border-color: var(--purple); }
    .decision-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .decision-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .decision-option.disabled { pointer-events: none; opacity: 0.7; }
    .decision-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .option-letter {
      width: 24px;
      height: 24px;
      background: rgba(255,255,255,0.1);
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 700;
      font-size: 0.8rem;
      flex-shrink: 0;
    }
    .decision-option.correct .option-letter { background: var(--green); color: white; }
    .decision-option.incorrect .option-letter { background: var(--red); color: white; }
    .option-text { font-size: 0.9rem; }
    .decision-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
    }
    .decision-feedback.show { display: block; }
    .decision-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .decision-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }
    .feedback-title { font-weight: 700; margin-bottom: 0.5rem; display: flex; align-items: center; gap: 0.5rem; }
    .feedback-text { font-size: 0.9rem; line-height: 1.5; }

    /* ====== QUIZ ====== */
    .quiz-container { width: 100%; max-width: 650px; }
    .quiz-question {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.2rem;
      margin-bottom: 1.25rem;
      text-align: center;
    }
    .quiz-options { display: flex; flex-direction: column; gap: 0.5rem; }
    .quiz-option {
      padding: 0.75rem 1rem;
      background: rgba(255,255,255,0.05);
      border: 2px solid rgba(255,255,255,0.2);
      border-radius: 8px;
      cursor: pointer;
      transition: all 0.2s;
      text-align: left;
      font-size: 0.9rem;
    }
    .quiz-option:hover { background: rgba(212,175,55,0.15); border-color: var(--gold); }
    .quiz-option.correct { background: rgba(34,197,94,0.2); border-color: var(--green); }
    .quiz-option.incorrect { background: rgba(239,68,68,0.15); border-color: var(--red); }
    .quiz-option.disabled { pointer-events: none; }
    .quiz-option:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .quiz-feedback {
      margin-top: 1rem;
      padding: 1rem;
      border-radius: 8px;
      display: none;
      font-size: 0.9rem;
    }
    .quiz-feedback.show { display: block; }
    .quiz-feedback.correct { background: rgba(34,197,94,0.2); border: 1px solid var(--green); }
    .quiz-feedback.incorrect { background: rgba(239,68,68,0.15); border: 1px solid var(--red); }

    /* Learning Objectives */
    .objectives-box {
      background: linear-gradient(135deg, rgba(59,130,246,0.15), rgba(30,39,97,0.25));
      border: 2px solid #3b82f6;
      border-radius: 12px;
      padding: 1.25rem;
      margin: 0.75rem 0;
      max-width: 700px;
      width: 100%;
    }
    .objectives-header {
      display: flex;
      align-items: center;
      gap: 0.75rem;
      margin-bottom: 0.75rem;
    }
    .objectives-icon {
      width: 36px;
      height: 36px;
      background: #3b82f6;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 1.1rem;
    }
    .objectives-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.1rem;
      font-weight: 700;
      color: #60a5fa;
    }
    .objectives-list { list-style: none; padding: 0; }
    .objectives-list li {
      display: flex;
      align-items: flex-start;
      gap: 0.5rem;
      padding: 0.4rem 0;
      font-size: 0.9rem;
    }
    .objectives-list li::before { content: '‚óã'; color: #3b82f6; font-weight: bold; }

    /* Animation */
    .slide.active .animate { animation: fadeUp 0.5s ease-out forwards; }
    .slide.active .animate.delay-1 { animation-delay: 0.1s; }
    .slide.active .animate.delay-2 { animation-delay: 0.2s; }
    .slide.active .animate.delay-3 { animation-delay: 0.3s; }
    @keyframes fadeUp {
      from { opacity: 0; transform: translateY(15px); }
      to { opacity: 1; transform: translateY(0); }
    }
    .animate { opacity: 0; }

    /* XP Popup */
    .xp-popup {
      position: fixed;
      top: 50%;
      left: 50%;
      transform: translate(-50%, -50%) scale(0);
      background: linear-gradient(135deg, var(--gold), #f0c040);
      color: var(--navy);
      padding: 1.5rem 2.5rem;
      border-radius: 12px;
      font-family: 'Cormorant Garamond', serif;
      font-size: 2rem;
      font-weight: 700;
      z-index: 1000;
      box-shadow: 0 10px 40px rgba(0,0,0,0.5);
      transition: transform 0.3s ease;
    }
    .xp-popup.show { transform: translate(-50%, -50%) scale(1); }
    .xp-popup .xp-amount { font-size: 3rem; display: block; }

    /* Badge Earned Modal */
    .badge-modal {
      position: fixed;
      top: 0; left: 0; right: 0; bottom: 0;
      background: rgba(0,0,0,0.85);
      display: none;
      justify-content: center;
      align-items: center;
      z-index: 1001;
    }
    .badge-modal.show { display: flex; }
    .badge-modal-content {
      background: linear-gradient(135deg, var(--deep-navy), #0a0f1a);
      border: 2px solid var(--gold);
      border-radius: 16px;
      padding: 2rem;
      text-align: center;
      max-width: 350px;
    }
    .badge-modal-icon { font-size: 4rem; margin-bottom: 1rem; }
    .badge-modal-title {
      font-family: 'Cormorant Garamond', serif;
      font-size: 1.5rem;
      color: var(--gold);
      margin-bottom: 0.5rem;
    }
    .badge-modal-desc { font-size: 0.9rem; opacity: 0.8; margin-bottom: 1rem; }
    .badge-modal-close {
      padding: 0.5rem 1.5rem;
      background: var(--gold);
      color: var(--navy);
      border: none;
      border-radius: 6px;
      font-weight: 600;
      cursor: pointer;
    }

    /* Confetti */
    .confetti-container {
      position: fixed;
      top: 0; left: 0;
      width: 100%; height: 100%;
      pointer-events: none;
      z-index: 999;
      overflow: hidden;
    }
    .confetti {
      position: absolute;
      width: 10px; height: 10px;
      opacity: 0;
      animation: confetti-fall 3s ease-out forwards;
    }
    @keyframes confetti-fall {
      0% { transform: translateY(-100px) rotate(0deg); opacity: 1; }
      100% { transform: translateY(100vh) rotate(720deg); opacity: 0; }
    }
    @media (prefers-reduced-motion: reduce) {
      .confetti { animation: none; display: none; }
      .xp-popup { transition: none; }
      .slide { transition: none; }
    }

    /* Nav */
    .slide-nav {
      position: absolute;
      bottom: 0; left: 0; right: 0;
      display: flex;
      justify-content: space-between;
      align-items: flex-end;
      padding: 0.75rem 1rem 1.25rem;
      z-index: 100;
      pointer-events: none;
    }
    .nav-btn {
      background: rgba(0,0,0,0.5);
      border: 1px solid rgba(255,255,255,0.2);
      color: white;
      font-size: 1.1rem;
      cursor: pointer;
      opacity: 0.6;
      transition: all 0.2s;
      padding: 0.4rem 0.6rem;
      border-radius: 6px;
      pointer-events: auto;
    }
    .nav-btn:hover { opacity: 1; background: rgba(0,0,0,0.7); border-color: var(--gold); }
    .nav-btn:disabled { opacity: 0.2; cursor: not-allowed; }
    .nav-btn:focus-visible { outline: 3px solid var(--gold); outline-offset: 2px; }
    .nav-center { display: flex; flex-direction: column; align-items: center; gap: 0.2rem; pointer-events: auto; }
    .slide-counter { font-size: 0.7rem; opacity: 0.5; }
    .progress-dots { display: flex; gap: 3px; flex-wrap: wrap; max-width: 220px; justify-content: center; }
    .progress-dot {
      width: 44px;
      height: 44px;
      display: flex;
      align-items: center;
      justify-content: center;
      cursor: pointer;
      background: none;
      border: none;
      padding: 0;
    }
    .progress-dot::after {
      content: '';
      width: 12px;
      height: 12px;
      border-radius: 50%;
      background: var(--text-muted, rgba(255,255,255,0.25));
      transition: all 0.2s ease;
    }
    .progress-dot.active::after,
    .progress-dot.completed::after {
      background: var(--gold);
      width: 14px;
      height: 14px;
    }

    /* Mobile */
    @media (max-width: 768px) {
      .sidebar {
        position: fixed;
        left: -300px;
        top: 0;
        bottom: 0;
        z-index: 1000;
        transition: left 0.3s ease;
      }
      .sidebar.open { left: 0; }
      .sidebar-toggle {
        display: flex;
        position: fixed;
        top: 10px;
        left: 10px;
        z-index: 1001;
        width: 40px;
        height: 40px;
        background: var(--gold);
        color: var(--navy);
        border: none;
        border-radius: 8px;
        align-items: center;
        justify-content: center;
        font-size: 1.2rem;
        cursor: pointer;
      }
      .sidebar-overlay {
        display: none;
        position: fixed;
        top: 0; left: 0; right: 0; bottom: 0;
        background: rgba(0,0,0,0.5);
        z-index: 999;
      }
      .sidebar-overlay.show { display: block; }
    }
    @media (min-width: 769px) {
      .sidebar-toggle { display: none; }
      .sidebar-overlay { display: none !important; }
    }

    /* Combo Counter */
    .combo-display {
      position: fixed;
      top: 80px;
      right: 20px;
      background: linear-gradient(135deg, var(--orange), #ef4444);
      color: white;
      padding: 0.5rem 1rem;
      border-radius: 20px;
      font-weight: 700;
      font-size: 0.9rem;
      z-index: 500;
      transform: scale(0);
      transition: transform 0.3s ease;
      box-shadow: 0 4px 15px rgba(239,68,68,0.4);
    }
    .combo-display.show { transform: scale(1); }
  </style>
</head>
<body>
<a class="skip-link" href="#main-content">Skip to main content</a>
<div class="course-container">
<!-- Sidebar -->
<nav aria-label="Navigazione del corso" class="sidebar" role="navigation">
<div class="sidebar-header">
<a href="index.html" onmouseout="this.style.color='rgba(212,175,55,0.7)'" onmouseover="this.style.color='#D4AF37'" style="display:block;font-size:0.7rem;color:rgba(212,175,55,0.7);text-decoration:none;margin-bottom:0.5rem;">‚Üê Course Library</a>
<h1>GRADE Mastery</h1>
<p>L'arte di giudicare le prove</p>
</div>
<div class="stats-panel">
<div class="level-display">
<div class="level-badge" id="levelIcon">üìä</div>
<div class="level-info">
<div class="level-title" id="levelTitle">Novice Appraiser</div>
<div class="level-subtitle">Level <span id="levelNum">1</span></div>
</div>
</div>
<div class="xp-bar"><div class="xp-fill" id="xpFill" style="width: 0%"></div></div>
<div class="xp-text"><span id="xpCurrent">0</span> / <span id="xpNeeded">100</span> XP</div>
<div class="quick-stats">
<div class="quick-stat">
<div class="quick-stat-value" id="correctCount">0</div>
<div class="quick-stat-label">Correct</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="decisionCount">0</div>
<div class="quick-stat-label">Decisions</div>
</div>
<div class="quick-stat">
<div class="quick-stat-value" id="gradesCount">0</div>
<div class="quick-stat-label">Graded</div>
</div>
</div>
</div>
<div class="course-progress">
<div class="course-progress-label">
<span>Course Progress</span>
<span id="courseProgressPct">0%</span>
</div>
<div class="course-progress-bar">
<div class="course-progress-fill" id="courseProgressFill" style="width: 0%"></div>
</div>
</div>
<div class="module-list" id="moduleList"></div>
<div class="badges-panel">
<div class="badges-title">Achievements</div>
<div class="badges-grid" id="badgesGrid"></div>
</div>
</nav>
<!-- Main Content -->
<main class="main-content" id="main-content">
<header class="content-header">
<div class="breadcrumb">GRADE Mastery / <span id="currentModule">Module 1</span></div>
<div class="header-actions">
<div class="streak-display" id="streakDisplay">
<span class="streak-flame">üî•</span>
<span class="streak-count" id="streakCount">0</span>
<span>day streak</span>
</div>
<button class="btn" onclick="resetProgress()">Reset</button>
</div>
</header>
<div class="content-body">
<div class="slides-container" id="slidesContainer"></div>
</div>
</main>
</div>
<!-- XP Popup -->
<div aria-atomic="true" aria-live="polite" class="xp-popup" id="xpPopup" role="status">
<span class="xp-amount" id="xpAmount">+25</span>
    XP
  </div>
<!-- Badge Modal -->
<div aria-labelledby="badgeModalTitle" aria-modal="true" class="badge-modal" id="badgeModal" role="dialog">
<div class="badge-modal-content">
<div class="badge-modal-icon" id="badgeModalIcon">üèÜ</div>
<div class="badge-modal-title" id="badgeModalTitle">Badge Earned!</div>
<div class="badge-modal-desc" id="badgeModalDesc">Hai sbloccato un nuovo obiettivo</div>
<button class="badge-modal-close" onclick="closeBadgeModal()">Awesome!</button>
</div>
</div>
<!-- Confetti Container -->
<div class="confetti-container" id="confettiContainer"></div>
<!-- Combo Counter -->
<div aria-live="polite" class="combo-display" id="comboDisplay" role="status">üî• <span id="comboCount">0</span>x Combo!</div>
<!-- Mobile Sidebar Toggle -->
<button aria-expanded="false" aria-label="Toggle menu" class="sidebar-toggle" onclick="toggleSidebar()">‚ò∞</button>
<div class="sidebar-overlay" id="sidebarOverlay" onclick="toggleSidebar()"></div>
<script>
// ===== GAMIFICATION STATE =====
const DEFAULT_STATE = {
  xp: 0,
  level: 1,
  streak: 0,
  lastActive: null,
  correctAnswers: 0,
  decisionsCompleted: 0,
  gradesAssigned: 0,
  badges: [],
  completedModules: [],
  answeredQuestions: {},
  consecutiveCorrect: 0
};

function safeGetStorage(key, fallback) {
  try {
    const item = localStorage.getItem(key);
    return item ? JSON.parse(item) : fallback;
  } catch (e) {
    return fallback;
  }
}

function safeSetStorage(key, value) {
  try {
    localStorage.setItem(key, JSON.stringify(value));
  } catch (e) {}
}

// Migration from old storage key to versioned key
(function migrateStorage() {
  try {
    const oldData = localStorage.getItem('gradeGame');
    if (oldData && !localStorage.getItem('gradeGame_v1')) {
      localStorage.setItem('gradeGame_v1', oldData);
      localStorage.removeItem('gradeGame');
    }
  } catch (e) {}
})();

let gameState = safeGetStorage('gradeGame_v1', DEFAULT_STATE);

const LEVELS = [
  { level: 1, title: "Novice Appraiser", icon: "üìä", xp: 0 },
  { level: 2, title: "Bias Spotter", icon: "üîç", xp: 100 },
  { level: 3, title: "Certainty Seeker", icon: "‚öñÔ∏è", xp: 250 },
  { level: 4, title: "Evidence Evaluator", icon: "üìã", xp: 450 },
  { level: 5, title: "GRADE Apprentice", icon: "üéì", xp: 700 },
  { level: 6, title: "Certainty Guardian", icon: "üõ°Ô∏è", xp: 1000 },
  { level: 7, title: "Evidence Master", icon: "üèÜ", xp: 1400 },
  { level: 8, title: "GRADE Sage", icon: "üëë", xp: 1900 }
];

const BADGES = [
  { id: "first_grade", icon: "üìä", name: "First Rating", desc: "Assign your first GRADE rating" },
  { id: "bias_hunter", icon: "üîç", name: "Bias Hunter", desc: "Completa il modulo Rischio di parzialit√†" },
  { id: "precision_master", icon: "üéØ", name: "Precision Master", desc: "Completa il modulo Imprecisione" },
  { id: "consistency_king", icon: "üîó", name: "Consistency King", desc: "Completa il modulo Incoerenza" },
  { id: "directness_detective", icon: "üé™", name: "Directness Detective", desc: "Completa il modulo Indiretta" },
  { id: "publication_sleuth", icon: "üì∞", name: "Publication Sleuth", desc: "Completa la distorsione della pubblicazione modulo" },
  { id: "upgrader", icon: "‚¨ÜÔ∏è", name: "The Upgrader", desc: "Learn all upgrading factors" },
  { id: "perfect_5", icon: "‚≠ê", name: "Five Star", desc: "Get 5 correct answers in a row" },
  { id: "decision_maker", icon: "‚öñÔ∏è", name: "Decision Maker", desc: "Completa 15 alberi decisionali" },
  { id: "finisher", icon: "üèÅ", name: "Course Complete", desc: "Termina l'intero corso" },
  { id: "streak_3", icon: "üî•", name: "On Fire", desc: "Maintain a 3-day streak" },
  { id: "streak_7", icon: "üí´", name: "Weekly Warrior", desc: "Maintain a 7-day streak" },
  { id: "grade_master", icon: "üëë", name: "GRADE Master", desc: "Completa la valutazione finale" }
];

// ===== MODULES DATA =====
const MODULES = [
  {
    id: 1, title: "Why Certainty Matters", subtitle: "When confidence kills", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Why Certainty Matters", subtitle: "When overconfidence in evidence kills patients" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why evidence certainty determines patient outcomes",
          "Impara dalle linee guida che hanno ucciso perch√© la certezza era mal giudicato",
          "Riconoscere la differenza tra 'le prove esistono' e 'le prove sono attendibili'",
          "Understand what GRADE provides that traditional reviews don't"
        ],
        tip: "Questo modulo mostra perch√© sbagliare nella certezza ha conseguenze reali."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "La catastrofe dei beta-bloccanti", title: "Guidelines Based on a Liar",
        text: "For two decades, clinical guidelines worldwide recommended <strong>beta-blockers before non-cardiac surgery</strong> to prevent heart attacks. The recommendation was rated 'strong'‚Äîhigh certainty of benefit. Millions of patients received the drugs before operations. The evidence came largely from one man: <strong>Don Poldermans</strong>, who contributed 15 studies showing dramatic benefits.",
        followup: "In 2011, Poldermans was found guilty of research misconduct. His data was fabricated. When his studies were removed from meta-analyses, the math reversed: beta-blockers didn't prevent heart attacks‚Äîthey caused them. Researchers calculated the cost: following guidelines based on this fraudulent 'high certainty' evidence may have <strong>killed 800,000 patients</strong> over a decade. The certainty rating was wrong. The patients paid with their lives."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Scenario: La forte raccomandazione",
        xp: 25,
        scenario: "Un panel di linee guida valuta l'evidenza come ‚Äúalta certezza‚Äù ed emette una ‚Äúforte raccomandazione‚Äù per un trattamento preventivo. Noti che il 60% delle prove proviene da un singolo gruppo di ricerca i cui risultati non sono mai stati replicati in modo indipendente.",
        question: "Che preoccupazione dovresti sollevare riguardo alla valutazione di certezza?",
        options: [
          { letter: "A", text: "Nessuno: gli studi sottoposti a revisione paritaria sono affidabili", correct: false },
          { letter: "B", text: "La certezza dovrebbe essere declassata per rischio di bias e mancanza di replica", correct: true },
          { letter: "C", text: "Richiedi pi√π studi allo stesso gruppo per confermare", correct: false },
          { letter: "D", text: "La forte raccomandazione compensa qualsiasi incertezza", correct: false }
        ],
        feedback: {
          correct: "Corretto! I risultati non replicati di Poldermans sono stati valutati con ‚Äúalta certezza‚Äù nonostante dipendessero da una fonte. Il GRADE richiede il declassamento quando le prove dipendono fortemente da fonti potenzialmente distorte che mancano di conferme indipendenti.",
          incorrect: "800.000 decessi sono il risultato della fiducia in prove non replicate provenienti da un'unica fonte. L'elevata certezza richiede una replica indipendente. La concentrazione in un solo gruppo di ricerca rappresenta un rischio critico di bias."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "L'inversione ormonale", title: "Two Million Women Betrayed",
        text: "For forty years, doctors prescribed <strong>hormone replacement therapy (HRT)</strong> to prevent heart disease in menopausal women. The evidence seemed overwhelming: observational studies showed <strong>50% fewer heart attacks</strong>. Experts were certain. Guidelines were strong. Two million American women took HRT specifically for heart protection.",
        followup: "In 2002, the Women's Health Initiative RCT delivered a verdict that shattered decades of certainty. HRT didn't prevent heart disease‚Äîit <strong>increased heart attacks by 29%</strong>, strokes by 41%, and breast cancer by 26%. The observational evidence had been confounded: healthy women chose HRT, creating an illusion of benefit. The certainty had been based on the wrong type of evidence. Two million women had taken a drug that harmed them, prescribed by doctors who were certain they were helping."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Scenario: Observational vs. RCT",
        xp: 25,
        scenario: "Venti ampi studi osservazionali mostrano che un trattamento riduce le morti cardiovascolari del 45%. Due piccoli RCT non mostrano alcun effetto. Un panel di linee guida deve valutare la certezza dell'evidenza per il beneficio.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Alto: 20 studi superano 2 studi", correct: false },
          { letter: "B", text: "Moderate‚Äîmixed evidence requires caution", correct: false },
          { letter: "C", text: "Low‚ÄîRCTs trump observational studies; confounding likely explains the discrepancy", correct: true },
          { letter: "D", text: "Very Low‚Äîno conclusion is possible", correct: false }
        ],
        feedback: {
          correct: "Corretto! Il disastro della HRT ci ha insegnato proprio questa lezione. Gli studi osservazionali che mostravano un beneficio del 50% sono stati superati dagli studi randomizzati che mostravano danni. Quando gli RCT contraddicono i dati osservativi, la probabile spiegazione √® la confusione. GRADE avvia gli RCT con un livello alto, osservativo con un livello basso.",
          incorrect: "HRT observational studies showed 50% benefit; the RCT showed 29% harm. The discrepancy was confounding‚Äîhealthy women chose HRT. RCT evidence, even from smaller studies, provides higher certainty than observational evidence for causal questions."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Il costo di una certezza sbagliata",
        stats: [
          { value: "800K", label: "Morti per frode di Polderman" },
          { value: "2M", label: "Women harmed by HRT" },
          { value: "50K", label: "CAST drug deaths" },
          { value: "83K", label: "Avandia heart attacks" }
        ],
        caption: "Ogni disastro prevedeva linee guida che erano \"certe\" sulla base di una valutazione di prove errate."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "L'intensivo Disastro del glucosio", title: "ACCORD: When Tight Control Killed",
        text: "Diabetes doctors were certain: if high blood sugar caused complications, then tighter glucose control must prevent them. The logic seemed irrefutable. Guidelines recommended <strong>aggressive targets</strong>. The ACCORD trial enrolled 10,251 patients to prove what everyone already 'knew'‚Äîintensive glucose control saves lives.",
        followup: "In February 2008, the trial was stopped early. Not for benefit‚Äî<strong>for harm</strong>. Intensive glucose control increased deaths by 22%. The certainty had been based on biological plausibility, not actual outcome data. The surrogate outcome (glucose levels) improved while the patient-important outcome (survival) worsened. 257 excess deaths occurred in the intensive group. The guidelines had been confident. The confidence was misplaced."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üéØ", title: "Scenario: il trattamento logico",
        xp: 25,
        scenario: "Un trattamento migliora notevolmente un biomarcatore (valore di laboratorio) noto per causare malattie. Nessuno studio ha ancora misurato i risultati clinici effettivi come la morte o il ricovero in ospedale. Un collega sostiene che la certezza del beneficio √® \"alta\" perch√© il meccanismo √® ben compreso.",
        question: "What certainty rating should apply?",
        options: [
          { letter: "A", text: "High‚Äîclear mechanism implies clear benefit", correct: false },
          { letter: "B", text: "Moderate‚Äîmechanism is supportive but not definitive", correct: false },
          { letter: "C", text: "Low or Very Low‚Äîsurrogate outcomes don't guarantee patient-important benefits", correct: true },
          { letter: "D", text: "Non √® possibile valutare fino al completamento delle sperimentazioni", correct: false }
        ],
        feedback: {
          correct: "Esatto! ACCORD, CAST e innumerevoli altri disastri seguirono l'errore del \"meccanismo logico\". Migliorare i surrogati pu√≤ peggiorare i risultati. Il GRADE richiede un declassamento indiretto quando vengono misurati solo i risultati surrogati.",
          incorrect: "La terapia intensiva ACCORD ha migliorato perfettamente il glucosio uccidendo i pazienti. I farmaci CAST hanno corretto gli ECG triplicando i decessi. La plausibilit√† biologica non √® un‚Äôevidenza clinica. Per avere un'elevata certezza sono necessari risultati importanti per il paziente."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "What GRADE Provides",
        subtitle: "Un quadro sistematico per la certezza",
        text: "GRADE (Grading of Recommendations Assessment, Development and Evaluation) fornisce un metodo strutturato e trasparente per valutare quanta fiducia dovremmo riporre nelle evidenze. Separa \"le prove esistono\" da \"le prove sono affidabili\".",
        highlight: "GRADE chiede: \"Quanto siamo sicuri che l'effetto reale si avvicini all'effetto stimato?\""
      }},
      { type: "story", theme: "dark", content: {
        label: "La rivelazione dell'artroscopia", title: "A Billion-Dollar Placebo",
        text: "Knee arthroscopy for osteoarthritis was one of the most common orthopedic procedures in the world. <strong>700,000 Americans</strong> underwent it annually at a cost of $3 billion. Surgeons were certain it worked‚Äîthey saw patients improve. Insurance covered it. Guidelines recommended it.",
        followup: "Then came the sham surgery trials. Patients were randomized to real arthroscopy or fake surgery (incisions but no actual procedure). The result: <strong>no difference</strong>. Patients improved equally whether they received real surgery or placebo. Decades of certainty, billions of dollars, millions of surgeries‚Äîall based on the placebo effect that surgeons couldn't see. The certainty had been based on uncontrolled observations. Controlled trials revealed the truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¨", title: "Scenario: il chirurgo esperto",
        xp: 25,
        scenario: "Un chirurgo esperto sostiene che una procedura \"funziona sicuramente\" perch√© l'ha eseguita 2.000 volte e 'visto pazienti migliorare.' Non esistono studi randomizzati. Vuole che la linea guida valuti la certezza come 'moderata' in base all'esperienza clinica.",
        question: "What certainty rating is appropriate?",
        options: [
          { letter: "A", text: "Moderate‚Äî2,000 cases is substantial experience", correct: false },
          { letter: "B", text: "Low‚Äîuncontrolled observations can't distinguish treatment effect from placebo", correct: true },
          { letter: "C", text: "Alta: l'esperienza degli esperti √® la forma di prova pi√π alta", correct: false },
          { letter: "D", text: "Molto bassa: gli aneddoti non sono prove", correct: false }
        ],
        feedback: {
          correct: "Corretto! I chirurghi di artroscopia del ginocchio hanno \"visto\" i pazienti migliorare per decenni, poi gli studi di chirurgia simulata hanno dimostrato che si trattava di un placebo. L'esperienza degli esperti non pu√≤ rilevare effetti placebo. GRADE valuta le osservazioni non controllate come una certezza molto bassa.",
          incorrect: "I chirurghi hanno eseguito 700.000 artroscopie all'anno, \"vedendo\" il beneficio: si trattava interamente di placebo. L'esperienza clinica, non importa quanto estesa, non √® in grado di distinguere gli effetti del trattamento dal miglioramento naturale o dal placebo. Gli studi randomizzati sono essenziali."
        }
      }},
      { type: "refrain", theme: "black", content: { text: "La certezza non riguarda quante prove esistono. Dipende da quanto dovremmo fidarci." }},
      { type: "quiz", theme: "dark", content: {
        question: "Perch√© gli studi osservazionali sulla terapia ormonale sostitutiva hanno indotto in errore i medici per 40 anni?",
        options: [
          { text: "Gli studi sono stati fabbricati", correct: false },
          { text: "Healthy women were more likely to choose HRT, creating confounding", correct: true },
          { text: "The RCTs used different doses", correct: false },
          { text: "Heart disease definitions changed over time", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Esattamente. Il confondimento dovuto alle indicazioni ‚Äì le donne sane sceglievano la terapia ormonale sostitutiva ‚Äì creava un‚Äôillusione di beneficio. Questo √® il motivo per cui il GRADE valuta gli studi osservazionali inferiori rispetto agli RCT per le domande causali.",
          incorrect: "Gli studi erano reali, ma confusi. Le donne sane avevano maggiori probabilit√† di assumere la terapia ormonale sostitutiva, facendola sembrare benefica. Gli studi randomizzati eliminano questo confondimento, rivelando il vero effetto."
        }
      }}
    ]
  },
  {
    id: 2, title: "Il quadro GRADE", subtitle: "Da alto a molto basso", xp: 120,
    slides: [
      { type: "title", theme: "dark", content: { title: "Il quadro GRADE", subtitle: "Four levels of certainty, five reasons to doubt" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Impara i quattro livelli di certezza GRADE e cosa significano",
          "Understand starting points: RCTs vs observational studies",
          "Conosci i cinque domini per il downgrade certezza",
          "Conoscere i tre fattori per migliorare l'evidenza osservativa"
        ],
        tip: "Questo modulo fornisce il quadro che applicherai durante il corso."
      }},
      { type: "stats", theme: "dark", content: {
        title: "I quattro livelli di certezza",
        stats: [
          { value: "‚äï‚äï‚äï‚äï", label: "HIGH" },
          { value: "‚äï‚äï‚äï‚óã", label: "MODERATE" },
          { value: "‚äï‚äï‚óã‚óã", label: "LOW" },
          { value: "‚äï‚óã‚óã‚óã", label: "VERY LOW" }
        ],
        caption: "Ogni livello indica ai decisori quanta fiducia riporre nel prove."
      }},
      { type: "concept", theme: "dark", content: {
        title: "What Each Level Means",
        subtitle: "Practical interpretation",
        checkpoints: [
          { day: "HIGH", event: "Molto fiducioso che l'effetto reale sia vicino alla stima" },
          { day: "MODERATE", event: "Moderately confident; true effect likely close but may differ" },
          { day: "LOW", event: "Limited confidence; true effect may be substantially different" },
          { day: "VERY LOW", event: "Very little confidence; true effect likely substantially different" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "Il principio del punto di partenza", title: "Why RCTs Begin Higher",
        text: "In 1747, James Lind conducted what many consider the first controlled trial. Twelve sailors with scurvy were divided into six pairs, each receiving a different treatment. <strong>Only the two who received citrus fruits recovered.</strong> This simple comparison‚Äîtreated vs. untreated under similar conditions‚Äîrevealed truth that centuries of observation had missed.",
        followup: "Randomization is the great equalizer. It balances known and unknown confounders between groups. When patients are randomized, differences in outcomes can be attributed to the treatment, not to differences between patients. This is why GRADE starts RCT evidence at <strong>HIGH</strong> certainty and observational evidence at <strong>LOW</strong>‚Äîthe study design itself determines how much confounding might distort results."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üé≤", title: "Scenario: il punto di partenza",
        xp: 25,
        scenario: "You're rating evidence for a new drug. You have three RCTs (total n=1,200) and five cohort studies (total n=45,000). A colleague argues the cohort studies should start at the same certainty level because they have more patients.",
        question: "Qual √® il punto di partenza corretto per ciascun tipo di prova?",
        options: [
          { letter: "A", text: "Both start at HIGH‚Äîsample size determines certainty", correct: false },
          { letter: "B", text: "RCTs start HIGH, cohorts start LOW‚Äîdesign determines starting point", correct: true },
          { letter: "C", text: "Cohorts start MODERATE because of large sample size", correct: false },
          { letter: "D", text: "Entrambi iniziano su MODERATO e regolare da l√¨", correct: false }
        ],
        feedback: {
          correct: "Corretto! I punti di partenza del GRADE si basano sul disegno dello studio, non sulla dimensione del campione. Gli RCT iniziano con ALTO perch√© la randomizzazione controlla il confondimento. Gli studi osservazionali iniziano con BASSO perch√© il confondimento non pu√≤ essere eliminato, indipendentemente dalle dimensioni.",
          incorrect: "Sample size affects precision, not confounding. The HRT cohort studies had millions of patients but were still wrong because of confounding. RCTs start HIGH; observational studies start LOW."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Cinque ambiti da declassare",
        items: [
          "Rischio di bias: gli studi sono ad alto rischio di bias?",
          "Incoerenza: i risultati variano inspiegabilmente da un paese all'altro studi?",
          "Indiretta: le prove rispondono direttamente alla nostra domanda?",
          "Imprecision ‚Äî Is the effect estimate precise enough?",
          "Bias della pubblicazione: mancano studi dalla base delle prove?"
        ]
      }},
      { type: "story", theme: "red-bg", content: {
        label: "La saga del Tamiflu", title: "When All Five Domains Failed",
        text: "In 2009, governments stockpiled Tamiflu for pandemic flu. The UK spent <strong>¬£473 million</strong>. The evidence looked solid: published trials showed reduced complications. But Cochrane reviewers noticed problems in every GRADE domain.",
        followup: "<strong>Risk of bias:</strong> Trials were industry-funded with unclear methods. <strong>Inconsistency:</strong> Results varied between published and unpublished studies. <strong>Indirectness:</strong> 'Complications' were poorly defined. <strong>Imprecision:</strong> Confidence intervals were wide. <strong>Publication bias:</strong> 60% of patient data was never published. When Roche finally released the raw data after five years, the truth emerged: Tamiflu reduced symptom duration by less than a day and had no proven effect on hospitalizations or complications. Half a billion pounds spent on evidence that should have been rated VERY LOW."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Scenario: il multi-dominio Problema",
        xp: 25,
        scenario: "You're rating evidence from 5 RCTs. You find: unclear allocation concealment (risk of bias), I¬≤ = 75% with no explanation (inconsistency), and half the trials never published (publication bias). The trials themselves are precise and direct.",
        question: "Di quanti livelli dovresti effettuare il downgrade da HIGH?",
        options: [
          { letter: "A", text: "One level‚Äîmultiple minor concerns equal one downgrade", correct: false },
          { letter: "B", text: "Two levels‚Äîserious concerns in two domains", correct: false },
          { letter: "C", text: "Three levels‚Äîserious concerns in three domains (to VERY LOW)", correct: true },
          { letter: "D", text: "Cannot downgrade RCTs‚Äîthey're always HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! Serious concerns in each domain typically warrant one downgrade each. Risk of bias (‚àí1), inconsistency (‚àí1), and publication bias (‚àí1) would take HIGH to VERY LOW. Multiple domains can compound.",
          incorrect: "Each domain with serious concerns typically warrants one downgrade. Three serious domain concerns = three downgrades. HIGH ‚àí 3 = VERY LOW. GRADE is cumulative."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Three Factors for Upgrading (Observational Only)",
        items: [
          "Large Effect ‚Äî Very large magnitude of effect (RR > 2 or < 0.5)",
          "Dose-Response ‚Äî Clear gradient between exposure and outcome",
          "Confounding ‚Äî All plausible confounding would reduce the effect"
        ]
      }},
      { type: "story", theme: "green-bg", content: {
        label: "La prova del fumo", title: "When Observation Earned Certainty",
        text: "In the 1950s, Richard Doll and Austin Bradford Hill published observational studies linking cigarettes to lung cancer. No RCTs existed‚Äîyou cannot randomize people to smoke. Yet the evidence became <strong>HIGH certainty</strong>. Why?",
        followup: "Every upgrading criterion was met. <strong>Large effect:</strong> Smokers had 10-30x higher lung cancer rates‚Äîan effect size that confounding alone cannot explain. <strong>Dose-response:</strong> More cigarettes = more cancer in a clear gradient. <strong>Confounding direction:</strong> Any unmeasured confounder that caused both smoking and cancer would have to be implausibly powerful to explain the effect. When observational evidence meets all three upgrading criteria, it can achieve certainty that rivals RCTs."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚¨ÜÔ∏è", title: "Scenario: La domanda di aggiornamento",
        xp: 25,
        scenario: "An observational study shows a treatment increases survival with RR = 1.3 (30% relative increase). The association is statistically significant with narrow confidence intervals. The authors argue this should be upgraded from LOW to MODERATE.",
        question: "Questa prova dovrebbe essere aggiornata?",
        options: [
          { letter: "A", text: "Yes‚Äîstatistical significance warrants upgrading", correct: false },
          { letter: "B", text: "Yes‚Äînarrow confidence intervals warrant upgrading", correct: false },
          { letter: "C", text: "No‚ÄîRR 1.3 is not large enough; confounding could easily explain it", correct: true },
          { letter: "D", text: "No‚Äîobservational evidence can never be upgraded", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 1.3 is well within the range that confounding can produce. Large effect upgrading typically requires RR > 2 or < 0.5‚Äîeffects so large that confounding alone is an implausible explanation. Statistical significance and precision are not upgrading criteria.",
          incorrect: "A 30% relative increase (RR 1.3) can easily result from modest confounding. The HRT studies showed RR 0.5 for heart protection‚Äîentirely due to confounding. Large effect upgrading requires effects that confounding cannot plausibly explain (typically RR > 2 or < 0.5)."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Il GRADE Mnemonico: RIIPP",
        subtitle: "Ricorda i 5 domini di downgrade",
        text: "<strong style='color:var(--gold);font-size:1.5rem'>R</strong>isk of bias ‚Äî Can we trust the studies?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>nconsistency ‚Äî Do studies agree?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>ndirectness ‚Äî Does evidence match our question?<br><br><strong style='color:var(--gold);font-size:1.5rem'>I</strong>mprecision ‚Äî Is the estimate precise?<br><br><strong style='color:var(--gold);font-size:1.5rem'>P</strong>ublication bias ‚Äî Is evidence missing?",
        highlight: "RIIPP ‚Äî Ricorda: 'Le prove RCT possono separarsi dal RIIPP se questi domini hanno problemi seri.'"
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why do observational studies start at LOW certainty in GRADE?",
        options: [
          { text: "They usually have smaller sample sizes", correct: false },
          { text: "They cannot control for unmeasured confounding", correct: true },
          { text: "They are more often industry-funded", correct: false },
          { text: "Richiedono pi√π tempo per essere completati", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Esattamente. La randomizzazione bilancia i fattori di confondimento tra i gruppi. Senza di essa, le differenze nei risultati potrebbero riflettere differenze nei pazienti, non effetti del trattamento. Gli studi sulla terapia ormonale sostitutiva con milioni di pazienti erano ancora sbagliati a causa della confusione.",
          incorrect: "Il problema √® la confusione, non la dimensione del campione. Gli studi osservazionali non possono bilanciare i fattori confondenti sconosciuti come fa la randomizzazione. Questa limitazione fondamentale determina il punto di partenza."
        }
      }}
    ]
  },
  {
    id: 3, title: "Risk of Bias", subtitle: "Quando gli studi mentono", xp: 180,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Risk of Bias", subtitle: "Il primo dominio: possiamo fidarci di questi studi?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Identificare i principali domini di bias negli studi randomizzati e osservazionali",
          "Recognize how bias inflates or deflates treatment effects",
          "Apply risk of bias assessment to real examples",
          "Decide when to downgrade certainty for bias"
        ],
        tip: "Completare tutti gli scenari decisionali per guadagnare il Bias Hunter distintivo!"
      }},
      { type: "story", theme: "red-bg", content: {
        label: "L'inganno di VIGOR", title: "When Merck Chose the Cutoff",
        text: "In 2000, Merck published the VIGOR trial comparing Vioxx to naproxen. The New England Journal of Medicine reported a 4-fold increase in heart attacks with Vioxx. But the published paper hid something: <strong>three additional heart attacks</strong> occurred in the Vioxx group after the data cutoff date. Merck scientists knew about them.",
        followup: "Those three heart attacks mattered. Including them would have changed the risk ratio from 'concerning' to 'alarming.' Instead, Merck's chosen cutoff date‚Äîa methodological decision made after seeing the data‚Äîobscured the true risk. The NEJM later published an 'expression of concern,' calling the paper 'inaccurate and incomplete.' By then, tens of thousands had suffered heart attacks from a drug whose danger had been hidden by selective reporting. The bias wasn't in the trial design‚Äîit was in how the data was analyzed and presented."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚úÇÔ∏è", title: "Scenario: Il limite mobile",
        xp: 30,
        scenario: "Stai valutando uno studio che ha modificato il suo timepoint di analisi primaria dopo l'inizio dello studio, da 12 mesi a 6 mesi. I risultati a 6 mesi favoriscono il trattamento. Gli autori affermano che la modifica √® stata apportata a causa di \"motivi amministrativi\" non correlati ai risultati.",
        question: "In che modo ci√≤ dovrebbe influire sul rischio di valutazione distorta?",
        options: [
          { letter: "A", text: "No concern‚Äîadministrative changes happen", correct: false },
          { letter: "B", text: "Alto rischio di bias per il reporting selettivo: i cambiamenti dei tempi dopo aver visualizzato i dati sono sospetti", correct: true },
          { letter: "C", text: "Basso rischio se anche i dati di 12 mesi sono segnalato", correct: false },
          { letter: "D", text: "Unclear risk‚Äîwe cannot know their true motivation", correct: false }
        ],
        feedback: {
          correct: "Esatto! Le modifiche post-hoc ai piani di analisi comportano un rischio elevato di reporting selettivo. L'interruzione dei dati di VIGOR √® stata una \"decisione metodologica\" che ha nascosto tre attacchi di cuore. Quando i punti temporali cambiano dopo che i dati si sono accumulati, presumi il peggio.",
          incorrect: "La data limite \"metodologica\" di Merck nascondeva attacchi di cuore fatali. I cambiamenti dell‚Äôanalisi post-hoc, soprattutto quando i risultati favoriscono il trattamento, rappresentano un classico reporting selettivo. GRADE richiede scetticismo riguardo alle modifiche post-hoc."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Il problema in aperto", title: "When Knowing Changes Everything",
        text: "The ASCOT-LLA trial compared atorvastatin to placebo for cardiovascular prevention. The primary endpoint was non-fatal MI plus fatal CHD‚Äî<strong>objective outcomes</strong> that shouldn't depend on whether doctors knew which treatment patients received.",
        followup: "But doctors did know. The trial was stopped early when the Data Safety Monitoring Board saw benefit. The problem: some outcomes were adjudicated by committees who were <strong>not blinded</strong> to treatment assignment. Did knowing a patient was on statin affect how borderline MIs were classified? Studies comparing blinded vs. unblinded assessment show systematic differences. Open-label designs can inflate apparent benefits by 10-20% even for 'objective' outcomes. ASCOT-LLA was rated down for risk of bias despite being an RCT."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üëÅÔ∏è", title: "Scenario: i valutatori non in cieco",
        xp: 25,
        scenario: "Un RCT di un intervento chirurgico riporta una riduzione del 30% degli \"eventi cardiovascolari maggiori\". Lo studio era necessariamente in cieco (i pazienti sapevano se avevano subito un intervento chirurgico). Anche i valutatori dei risultati non erano in cieco. Gli eventi sono stati giudicati da un comitato che conosceva le assegnazioni dei trattamenti.",
        question: "Qual √® il rischio di bias di rilevamento?",
        options: [
          { letter: "A", text: "Low‚Äîcardiovascular events are objective", correct: false },
          { letter: "B", text: "High‚Äîunblinded assessment of cardiovascular events inflates effects", correct: true },
          { letter: "C", text: "Non chiaro: abbiamo bisogno di ulteriori informazioni sul comitato", correct: false },
          { letter: "D", text: "Not applicable‚Äîsurgical trials cannot be blinded", correct: false }
        ],
        feedback: {
          correct: "Correct! Even 'objective' outcomes like MI involve judgment calls (borderline troponins, ECG interpretations). Studies show unblinded assessment inflates effects 10-20%. Outcome assessors should always be blinded when possible, regardless of intervention blinding.",
          incorrect: "Cardiovascular events require interpretation‚Äîborderline troponin elevations, ECG changes, symptom classification. Unblinded assessors systematically favor the intervention. Outcome assessment should be blinded even when intervention blinding is impossible."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "La violazione ITT", title: "Roche's Missing Patients",
        text: "In Tamiflu trials, Roche excluded patients from analysis after randomization. Some were excluded for 'protocol violations'‚Äîbut the violations often occurred <strong>after</strong> patients had taken the drug and experienced side effects. Patients who developed complications were retroactively deemed 'protocol violators' and removed.",
        followup: "Intention-to-treat (ITT) analysis exists precisely to prevent this. Once randomized, always analyzed‚Äîregardless of what happens afterward. Excluding patients after randomization destroys the balance that randomization created. Roche's selective exclusions removed patients who had adverse outcomes, making Tamiflu appear safer and more effective than it was. The Cochrane review downgraded certainty specifically for these ITT violations."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üö™", title: "Scenario: la post-randomizzazione Esclusioni",
        xp: 25,
        scenario: "A trial randomizes 500 patients per arm. The paper reports results for 420 vs. 380 patients, with 80 and 120 exclusions respectively. Reasons include: 'withdrew consent,' 'lost to follow-up,' and 'protocol deviation.' More patients were excluded from the control arm.",
        question: "What risk of bias concern does this raise?",
        options: [
          { letter: "A", text: "No concern‚Äîexclusions happen in every trial", correct: false },
          { letter: "B", text: "High risk of attrition bias‚Äîdifferential exclusions destroy randomization balance", correct: true },
          { letter: "C", text: "Low risk if reasons are documented", correct: false },
          { letter: "D", text: "Unclear‚Äîwe need to know why controls were excluded more", correct: false }
        ],
        feedback: {
          correct: "Corretto! L'attrito differenziale (120 contro 80 esclusioni) suggerisce che i gruppi non sono pi√π comparabili. Se i pazienti di controllo che non miglioravano avessero maggiori probabilit√† di abbandonare lo studio, i restanti controlli apparirebbero pi√π sani di quanto dovrebbero. Ci√≤ aumenta il beneficio apparente del trattamento.",
          incorrect: "Le esclusioni differenziali (120 contro 80) interrompono la randomizzazione. I restanti gruppi non sono pi√π equilibrati. Se i pazienti di controllo pi√π malati abbandonavano lo studio, il gruppo di controllo appariva artificialmente sano. GRADE richiede il downgrade per un sostanziale attrito differenziale."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Il divario di registrazione", title: "I risultati che sono scomparsi",
        text: "A systematic review of trial registration found that <strong>31% of trials</strong> changed their primary outcome between registration and publication. The changes weren't random‚Äîthey systematically favored positive results. Outcomes that showed benefit were promoted to primary; outcomes showing no effect were demoted or disappeared.",
        followup: "Selective outcome reporting is invisible without registration comparison. A trial might register five outcomes, find benefit in one, and publish only that one as the 'primary' outcome. The reader sees a positive trial. The reality: 4 of 5 outcomes showed nothing. PROSPERO registration for systematic reviews and ClinicalTrials.gov for trials exist specifically to combat this. When assessing risk of bias, always compare published outcomes to registered protocols."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìã", title: "Scenario: The Primary Outcome Switch",
        xp: 25,
        scenario: "Si confronta uno studio pubblicato con la sua registrazione. La registrazione elenca la \"morte cardiovascolare\" come primaria. La pubblicazione elenca il \"composito di morte CV, infarto miocardico o ictus\" come primario e lo riporta come significativo. La sola morte cardiovascolare √® sepolta in una tabella e non mostra differenze significative.",
        question: "What risk of bias rating is appropriate?",
        options: [
          { letter: "A", text: "Low‚Äîcomposite endpoints are clinically reasonable", correct: false },
          { letter: "B", text: "High‚Äîthis is outcome switching to achieve significance", correct: true },
          { letter: "C", text: "Unclear‚Äîthe authors may have had good reasons", correct: false },
          { letter: "D", text: "Basso se il composito √® stato pre-specificato nel protocollo", correct: false }
        ],
        feedback: {
          correct: "Corretto! Passare da un risultato ristretto (morte CV) a un composito pi√π ampio (morte CV/IM/ictus) dopo aver visto che il risultato ristretto ha fallito √® un cambiamento di risultato da manuale. Il 31% degli studi che lo fanno gonfiano sistematicamente i risultati positivi.",
          incorrect: "Si tratta di un cambiamento di risultato: le primarie registrate sono fallite, quindi √® stato promosso un composito pi√π ampio. Il significato composito pu√≤ essere determinato interamente dalle componenti meno importanti. Confronta ogni pubblicazione con la sua registrazione."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "L'audit Avandia", title: "38,000 Heart Attacks Exposed by One Cardiologist",
        text: "In 2007, Dr. Steven Nissen at the Cleveland Clinic did what regulators hadn't: he pooled all available rosiglitazone (Avandia) data. <strong>42 trials, 27,847 patients</strong>. The FDA had approved Avandia based on surrogate outcomes‚Äîit lowered blood sugar beautifully. But Nissen asked a different question: what about hearts?",
        followup: "His meta-analysis revealed the truth: Avandia increased heart attacks by <strong>43%</strong> (OR 1.43, 95% CI 1.03-1.98). GSK had conducted these trials. GSK had the data. But the data on cardiovascular events had been scattered across trials, buried in adverse event tables, never pooled. When Nissen pooled it, the pattern became undeniable. The FDA estimated <strong>83,000 excess heart attacks</strong> between 1999-2007. The bias wasn't in study conduct‚Äîit was in how results were analyzed and presented. Selective synthesis can be as dangerous as selective reporting."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìë", title: "Scenario: i dati di sicurezza sparsi",
        xp: 25,
        scenario: "A drug has been studied in 30 trials for various conditions. Each trial reports a few adverse cardiac events in supplementary tables, but no single trial was powered for cardiac outcomes. A meta-analysis combining cardiac events across all 30 trials shows RR 1.35 (95% CI 1.10-1.65) for heart attacks.",
        question: "How should this post-hoc safety signal affect certainty?",
        options: [
          { letter: "A", text: "Ignore it‚Äîtrials weren't designed for cardiac outcomes", correct: false },
          { letter: "B", text: "Prendilo sul serio: gli eventi avversi raggruppati possono rivelare segnali reali anche da un'analisi post-hoc", correct: true },
          { letter: "C", text: "Dismiss it‚Äîmeta-analysis of adverse events is unreliable", correct: false },
          { letter: "D", text: "Wait for a dedicated cardiac outcome trial before acting", correct: false }
        ],
        feedback: {
          correct: "Esatto! L'analisi Avandia di Nissen consisteva in un raggruppamento \"post-hoc\" di eventi avversi sparsi e ha rivelato un eccesso di 83.000 attacchi cardiaci. I segnali di sicurezza post-hoc derivanti dalla meta-analisi possono essere reali. L'assenza di esiti cardiaci pre-specificati non significa che non si siano verificati eventi cardiaci.",
          incorrect: "Il caso Avandia ha dimostrato che il raggruppamento post-hoc degli eventi avversi pu√≤ rivelare un danno reale. Aspettare un processo dedicato mentre si accumulavano 83.000 infarti sarebbe stato inconcepibile. I segnali di sicurezza provenienti dalla meta-analisi degli eventi avversi meritano una seria considerazione."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "L'inganno ENHANCE", title: "When Merck Hid What They Found",
        text: "Nel 2006, Merck ha completato lo studio ENHANCE su Vytorin (ezetimibe + simvastatina) per l'aterosclerosi. Lo studio ha misurato lo spessore dell‚Äôarteria carotide, un surrogato delle malattie cardiovascolari. I risultati sarebbero dovuti arrivare all'inizio del 2007. Merck ha annunciato un 'ritardo' per 'ulteriori analisi'.",
        followup: "The 'additional analyses' took <strong>two years</strong>. When finally released in 2008, ENHANCE showed <strong>no benefit</strong>‚ÄîVytorin didn't reduce artery thickness despite lowering LDL cholesterol. During those two years of concealment, Vytorin sales exceeded <strong>$5 billion</strong>. Congressional investigations revealed internal documents showing Merck knew the results were negative in 2006. The delay wasn't for analysis‚Äîit was for commercial protection. Publication delay is a form of selective reporting: timing becomes a bias tool."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚è∞", title: "Scenario: il ritardo sospetto",
        xp: 25,
        scenario: "Uno studio altamente atteso di un farmaco di successo avrebbe dovuto riportare i risultati 18 mesi fa. L'azienda cita \"analisi in corso\" e \"problemi di qualit√† dei dati\". Nel frattempo, il farmaco continua a vendere miliardi ogni anno. Le prove dei concorrenti sono gi√† state riportate.",
        question: "Cosa dovresti sospettare sui risultati non riportati?",
        options: [
          { letter: "A", text: "Nothing‚Äîdata quality takes time", correct: false },
          { letter: "B", text: "Likely negative or harmful‚Äîcompanies delay bad news, not good news", correct: true },
          { letter: "C", text: "Likely positive‚Äîthey're waiting for regulatory approval", correct: false },
          { letter: "D", text: "Cannot infer anything from publication timing", correct: false }
        ],
        feedback: {
          correct: "Correct! The ENHANCE delay taught us: companies don't delay good news for two years. Unexplained publication delays, especially for products still generating revenue, are strong evidence of unfavorable results. Consider delayed trials as potentially biased against the intervention.",
          incorrect: "I tempi di pubblicazione sono informativi. Le aziende accelerano la pubblicazione dei risultati positivi (prezzo delle azioni, marketing) e ritardano quelli negativi (vendite continue). Un ritardo di 18 mesi per un farmaco di successo suggerisce fortemente che i risultati non supportano l'uso continuato."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Risk of Bias Domains (RCTs)",
        items: [
          "Random sequence generation ‚Äî Was randomization truly random?",
          "Allocation concealment ‚Äî Could anyone predict assignments?",
          "Blinding of participants/personnel ‚Äî Did they know treatment?",
          "Blinding of outcome assessment ‚Äî Did assessors know treatment?",
          "Dati sui risultati incompleti: l'attrito era bilanciato e spiegato?",
          "Selective reporting ‚Äî Are registered outcomes all reported?",
          "Other bias ‚Äî Baseline imbalances, early stopping, etc."
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE downgrade for open-label outcome assessment even when outcomes seem 'objective'?",
        options: [
          { text: "Open-label trials are always lower quality", correct: false },
          { text: "Even objective outcomes involve judgment calls affected by knowledge of treatment", correct: true },
          { text: "Regulations require blinded assessment", correct: false },
          { text: "√à una convenzione conservativa, non basata su prove", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Giusto! Infarto miocardico borderline, sintomi di ictus incerti, cambiamenti discutibili dell'ECG: tutti implicano un'interpretazione. Gli studi mostrano che la valutazione in cieco favorisce sistematicamente il trattamento noto del 10-20% anche per gli endpoint \"hard\".",
          incorrect: "La ricerca mostra che la valutazione in cieco gonfia gli effetti anche per i risultati che sembrano oggettivi. I casi limite vengono interpretati a favore dell'effetto atteso. Questo √® un bias di rilevamento."
        }
      }}
    ]
  },
  {
    id: 4, title: "Inconsistency", subtitle: "Quando gli studi non sono d'accordo", xp: 160,
    slides: [
      { type: "title", theme: "orange-bg", content: { title: "Inconsistency", subtitle: "Il secondo dominio: cosa facciamo quando gli studi non sono d'accordo?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Capire perch√© i risultati degli studi variano e quando la variazione √® preoccupante",
          "Interpretare le statistiche I¬≤ e tau¬≤ per l'eterogeneit√†",
          "Distinguish explainable from unexplainable inconsistency",
          "Decide when to downgrade certainty for inconsistency"
        ],
        tip: "Real disagreement between studies tells us something important."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "La vitamina D Contraddizione", title: "Quando 200 studi non riuscivano a concordare",
        text: "By 2019, over <strong>200 randomized trials</strong> had studied vitamin D supplementation. The results were chaos. Some showed vitamin D prevented cancer (RR 0.77). Others showed no effect (RR 1.02). Some showed harm (RR 1.15). Meta-analyses pooled them all and proclaimed 'statistically significant benefit.' But the I¬≤ was <strong>78%</strong>‚Äîmassive heterogeneity that the summary estimate concealed.",
        followup: "The largest trial, VITAL (25,871 participants), finally brought clarity. It showed <strong>no benefit</strong> for cancer or cardiovascular disease. The smaller positive studies had methodological problems: inadequate randomization, post-hoc analyses, selected populations. The pooled estimate had hidden a crucial truth: when studies wildly disagree, the average may represent no one's truth. GRADE requires downgrading for this kind of inconsistency, regardless of what the pooled estimate shows."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Scenario: la meta-analisi eterogenea",
        xp: 25,
        scenario: "A meta-analysis of 15 trials shows pooled benefit (OR 0.75, p<0.001). However, I¬≤ = 82%, tau¬≤ is large, and the prediction interval crosses 1.0. Six trials show harm, nine show benefit. The authors conclude 'significant benefit with moderate heterogeneity.'",
        question: "How should inconsistency affect the certainty rating?",
        options: [
          { letter: "A", text: "No downgrade‚Äîthe pooled estimate is statistically significant", correct: false },
          { letter: "B", text: "Downgrade one level‚ÄîI¬≤ > 75% is substantial heterogeneity", correct: false },
          { letter: "C", text: "Downgrade one or two levels‚Äîprediction interval crossing 1.0 means future studies might show harm", correct: true },
          { letter: "D", text: "Cannot rate‚Äîinconsistent evidence is uninterpretable", correct: false }
        ],
        feedback: {
          correct: "Correct! The prediction interval is key. When it crosses the null, we're saying: 'If we did another study, it might show the opposite effect.' That's profound uncertainty. I¬≤ = 82% with a prediction interval crossing 1.0 warrants serious downgrading.",
          incorrect: "I¬≤ dell'82% √® una grave eterogeneit√†, ma l'intervallo di previsione √® pi√π informativo. Superare 1.0 significa che studi futuri potrebbero mostrare danni: il \"beneficio\" complessivo potrebbe non applicarsi al paziente successivo. La significativit√† statistica della stima aggregata non salva prove incoerenti."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Il mistero dell'ictus", title: "Aspirin's Vanishing Benefit",
        text: "In 1988, the ISIS-2 trial proved aspirin reduced death after heart attack by <strong>23%</strong>. The evidence was bulletproof‚Äî17,187 patients, clear benefit, minimal heterogeneity when pooled with similar trials. Aspirin became standard care.",
        followup: "But stroke prevention was different. Meta-analyses of aspirin for primary prevention showed <strong>wildly inconsistent results</strong>. Some trials showed 15% reduction in stroke. Others showed 10% increase. The I¬≤ exceeded 60%. The explanation emerged slowly: aspirin prevents <strong>ischemic</strong> stroke but causes <strong>hemorrhagic</strong> stroke. When trials measured 'all stroke,' results depended on the baseline mix of stroke types in each population. The inconsistency wasn't noise‚Äîit was biology. Understanding <em>why</em> studies differ changes interpretation entirely."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Scenario: l'incoerenza spiegabile",
        xp: 25,
        scenario: "A meta-analysis shows I¬≤ = 70%. However, subgroup analysis reveals: trials in high-risk patients show consistent benefit (I¬≤ = 15%, OR 0.60), while trials in low-risk patients show consistent null effects (I¬≤ = 20%, OR 1.02). The high I¬≤ is entirely explained by mixing these populations.",
        question: "Dovresti eseguire il downgrade per incoerenza?",
        options: [
          { letter: "A", text: "Yes‚ÄîI¬≤ = 70% always requires downgrading", correct: false },
          { letter: "B", text: "No‚Äîinconsistency is fully explained by a pre-specified, biologically plausible subgroup", correct: true },
          { letter: "C", text: "Partially‚Äîdowngrade one level despite the explanation", correct: false },
          { letter: "D", text: "Report two separate certainty ratings for each subgroup", correct: false }
        ],
        feedback: {
          correct: "Esatto! GRADE distingue l'eterogeneit√† inspiegabile (downgrade) dall'eterogeneit√† pienamente spiegata da effetti di sottogruppo credibili (nessun downgrade per incoerenza). La spiegazione deve essere pre-specificata e biologicamente plausibile, non dragaggio di dati post-hoc.",
          incorrect: "When heterogeneity is fully explained by a pre-specified, credible subgroup effect, the 'inconsistency' actually tells us something useful: treatment works differently in different populations. This informs clinical practice rather than undermining certainty."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Il paradosso dell'albumina", title: "28 Trials, Zero Answers",
        text: "Should critically ill patients receive albumin for fluid resuscitation? By 1998, the Cochrane Injuries Group had pooled <strong>28 trials</strong>. Their conclusion: albumin <strong>increases mortality by 68%</strong> (RR 1.68). Headlines screamed. NHS considered banning albumin. The evidence seemed damning.",
        followup: "But look closer at those 28 trials. I¬≤ was <strong>0%</strong>‚Äîno heterogeneity. A different problem lurked: the trials were tiny (many with <50 patients), measured different populations (burns, trauma, surgery), and many were decades old. The <strong>SAFE trial</strong> (6,997 patients, 2004) finally answered the question: albumin was <strong>equivalent to saline</strong>‚Äîno benefit, no harm. The pooled estimate from 28 small, disparate trials had been an artifact of random variation in underpowered studies, not a real signal. Consistency (low I¬≤) doesn't guarantee truth."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚öñÔ∏è", title: "Scenario: prove coerenti ma preoccupanti",
        xp: 25,
        scenario: "A meta-analysis pools 12 small trials (total n=400) with I¬≤ = 5%‚Äîvery low heterogeneity. The pooled effect is OR 0.50 (dramatic benefit), statistically significant. A colleague argues this deserves HIGH certainty because results are 'beautifully consistent.'",
        question: "What concern should you raise?",
        options: [
          { letter: "A", text: "None‚Äîlow I¬≤ means high certainty for inconsistency", correct: false },
          { letter: "B", text: "Low I¬≤ in small trials may reflect consistent bias, not consistent truth", correct: true },
          { letter: "C", text: "I¬≤ = 5% is too low and suggests publication bias", correct: false },
          { letter: "D", text: "The pooled estimate is too dramatic to be real", correct: false }
        ],
        feedback: {
          correct: "Corretto! Piccoli studi con risultati consistenti e drammatici dovrebbero suscitare sospetti. Possono condividere gli stessi pregiudizi (bias di pubblicazione, metodi simili imperfetti). La meta-analisi dell‚Äôalbumina ha evidenziato un I¬≤ vicino allo 0% in 28 studi, ma l‚Äôampio studio SAFE ha mostrato un effetto nullo. Coerenza in piccoli studi ‚â† verit√†.",
          incorrect: "Low heterogeneity among small, potentially biased trials can be misleading. If all trials share similar biases (publication bias, poor methods), they'll show consistently biased results. The albumin case proves this: I¬≤ was low, but the effect was an artifact."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "Understanding I¬≤ Thresholds",
        stats: [
          { value: "0-25%", label: "Low heterogeneity" },
          { value: "25-50%", label: "Moderate" },
          { value: "50-75%", label: "Substantial" },
          { value: ">75%", label: "Considerable" }
        ],
        caption: "Ma I¬≤ da solo non determina il declassamento: l'intervallo di previsione e il significato clinico contano di pi√π."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Inconsistency Assessment Checklist",
        items: [
          "Calculate I¬≤ and tau¬≤ ‚Äî but don't stop there",
          "Examine prediction interval ‚Äî does it cross clinically important thresholds?",
          "Cercare intervalli di confidenza sovrapposti tra gli studi",
          "Check if heterogeneity can be explained by credible subgroups",
          "Consider if small trials are driving inconsistency (vs. large trial disagreement)"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Perch√© l'intervallo di previsione √® pi√π importante di I¬≤ per l'incoerenza GRADE valutazione?",
        options: [
          { text: "Prediction intervals are easier to calculate", correct: false },
          { text: "Prediction intervals tell us what effect a future study might show", correct: true },
          { text: "I¬≤ is only valid for large meta-analyses", correct: false },
          { text: "Prediction intervals account for publication bias", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The prediction interval says: 'The next study from this distribution of effects will probably fall in this range.' If that range includes harm while the pooled estimate shows benefit, we're deeply uncertain about what will happen to the next patient.",
          incorrect: "The prediction interval captures uncertainty about what future studies (or the next patient) might experience. I¬≤ tells us whether heterogeneity exists; the prediction interval tells us whether it matters clinically."
        }
      }}
    ]
  },
  {
    id: 5, title: "Indirectness", subtitle: "Domanda sbagliata, risposta sbagliata", xp: 170,
    slides: [
      { type: "title", theme: "purple-bg", content: { title: "Indirectness", subtitle: "Il terzo dominio: questa prova risponde alla nostra vera domanda?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Recognize four types of indirectness: population, intervention, comparator, outcome",
          "Understand why surrogate outcomes mislead",
          "Apply indirectness assessment to real scenarios",
          "Decide when evidence is too indirect to trust"
        ],
        tip: "La migliore prova per la domanda sbagliata √® ancora la risposta sbagliata."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Il CAST Catastrofe", title: "50.000 morti a causa di un trattamento logico",
        text: "After a heart attack, arrhythmias predict death. <strong>Encainide and flecainide</strong> suppressed arrhythmias on ECG beautifully‚Äî85% reduction in premature ventricular contractions. The FDA approved them. Cardiologists prescribed them to hundreds of thousands of post-MI patients. The logic was irresistible: dangerous arrhythmias ‚Üí sudden death; suppress arrhythmias ‚Üí prevent death.",
        followup: "The CAST trial was designed to confirm what everyone already 'knew.' Instead, it delivered a verdict that stunned cardiology. Patients on anti-arrhythmic drugs died at <strong>3.6 times the rate</strong> of placebo. The trials were stopped early for harm. An estimated <strong>50,000 Americans died</strong> from drugs that perfectly fixed the surrogate (ECG) while causing the outcome (death). The evidence for arrhythmia suppression was HIGH certainty‚Äîbut it was indirect evidence for mortality. That indirectness killed 50,000 people."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìà", title: "Scenario: il surrogato perfetto",
        xp: 25,
        scenario: "Un nuovo farmaco per il diabete mostra una drastica riduzione dell'HbA1c (miglioramento dell'1,5% rispetto al placebo). L'azienda sostiene che, poich√© l'HbA1c √® un ‚Äúsurrogato validato‚Äù degli esiti cardiovascolari, la certezza del beneficio cardiovascolare dovrebbe essere valutata MODERATA. Non esistono ancora studi sugli esiti CV.",
        question: "Come valutare la certezza del beneficio cardiovascolare?",
        options: [
          { letter: "A", text: "MODERATE‚ÄîHbA1c is a validated surrogate", correct: false },
          { letter: "B", text: "HIGH‚Äî1.5% reduction is clinically meaningful", correct: false },
          { letter: "C", text: "LOW or VERY LOW‚Äîdowngrade for indirectness (surrogate outcome)", correct: true },
          { letter: "D", text: "Cannot rate until CV trials are conducted", correct: false }
        ],
        feedback: {
          correct: "Correct! ACCORD showed intensive HbA1c lowering <em>increased</em> deaths. Rosiglitazone lowered HbA1c while increasing heart attacks. Surrogate outcomes require downgrading for indirectness, no matter how 'validated' they seem. Patient-important outcomes are required for high certainty.",
          incorrect: "CAST drugs fixed ECGs while tripling deaths. ACCORD lowered HbA1c while increasing mortality. 'Validated surrogates' have repeatedly failed. GRADE requires downgrading one or two levels when only surrogate outcomes are measured."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Il tradimento della densit√† ossea", title: "When Stronger Bones Broke More",
        text: "Sodium fluoride increased bone mineral density dramatically‚Äî<strong>8% improvement per year</strong>. For osteoporosis, this seemed like a miracle. Bone density was the accepted surrogate for fracture risk. Higher density = fewer fractures. The math seemed inescapable.",
        followup: "Then came the trials measuring actual fractures. Sodium fluoride <strong>increased</strong> fracture rates despite improving bone density. The explanation: fluoride created dense but brittle bone‚Äîlike adding quantity without quality. The surrogate (density) moved in the right direction while the patient-important outcome (fractures) moved in the wrong direction. This case became a landmark in surrogate outcome skepticism."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü¶¥", title: "Scenario: The Bone Drug Decision",
        xp: 25,
        scenario: "A new osteoporosis drug shows 4% improvement in bone mineral density at 2 years. The company presents evidence of reduced fractures, but the fracture trials used a different formulation and dose than the one being approved. The FDA asks you to rate certainty of fracture benefit for the approved formulation.",
        question: "What indirectness concern applies?",
        options: [
          { letter: "A", text: "No concern‚Äîbone density is a validated surrogate", correct: false },
          { letter: "B", text: "Indiretto per l'intervento: √® stata testata una formulazione/dose diversa", correct: true },
          { letter: "C", text: "Indirect for population‚Äîfracture trials may have different patients", correct: false },
          { letter: "D", text: "Indiretto per l'esito: le fratture non sono paziente-importante", correct: false }
        ],
        feedback: {
          correct: "Esatto! L‚Äôindirettazza pu√≤ applicarsi all‚Äôintervento, alla popolazione, al comparatore o al risultato. In questo caso, la formulazione/dose testata per le fratture differisce da quella approvata. Non possiamo assumere l'equivalenza. Ci√≤ richiede il declassamento per l'intervento indiretto.",
          incorrect: "L'evidenza di frattura deriva da una formulazione e una dose diverse. Stiamo estrapolando dal farmaco A alla dose X al farmaco A alla dose Y. Questo √® un intervento indiretto: le prove non testano direttamente ci√≤ che stiamo approvando."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Il calcolo del rosiglitazone", title: "FDA's 2.5 Million Patient Gamble",
        text: "In 2007, cardiologist Steven Nissen published a meta-analysis showing rosiglitazone (Avandia) increased heart attacks by <strong>43%</strong>. The drug had been prescribed to millions based on glucose control. But no large outcome trial had ever been required.",
        followup: "The FDA's logic had been: diabetes causes heart disease ‚Üí better glucose control should prevent it. That's <strong>indirectness</strong>‚Äîassuming a chain of causation without testing the final link. The FDA estimated rosiglitazone caused <strong>83,000 excess heart attacks</strong> before restrictions were imposed. The European Medicines Agency suspended it entirely. A drug approved on indirect evidence had harmed more patients than it helped."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Scenario: il divario testa a testa",
        xp: 25,
        scenario: "√à necessario confrontare il farmaco A vs. Farmaco B per le tue linee guida. Non esistono prove testa a testa. Hai: Farmaco A vs placebo (RR 0,70) e Farmaco B vs placebo (RR 0,65) da studi separati in diverse popolazioni condotti a 10 anni di distanza.",
        question: "What type of indirectness applies?",
        options: [
          { letter: "A", text: "No indirectness‚Äîwe can compare the two placebo-controlled estimates", correct: false },
          { letter: "B", text: "Indirect comparisons require downgrading‚Äîdifferent trials break randomization", correct: true },
          { letter: "C", text: "Solo indiretto per la popolazione, non per confronto", correct: false },
          { letter: "D", text: "Network meta-analysis solves this indirectness", correct: false }
        ],
        feedback: {
          correct: "Correct! Comparing across trials breaks randomization. Drug A's trial may have sicker patients, different background care, different outcome definitions. The RR difference (0.70 vs. 0.65) may reflect trial differences, not drug differences. GRADE calls this 'indirect comparison' and requires downgrading.",
          incorrect: "I confronti indiretti sono fondamentalmente diversi dagli studi testa a testa. Quando confrontiamo il farmaco A rispetto al placebo (esperimento 1) con il farmaco B rispetto al placebo (esperimento 2), qualsiasi differenza tra gli studi diventa confondente. La meta-analisi di rete aiuta ma non elimina questo aspetto indiretto."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "L'estrapolazione di oseltamivir", title: "Dal laboratorio alla clinica alla menzogna",
        text: "Tamiflu (oseltamivir) was approved based on trials showing it reduced <strong>symptom duration by 21 hours</strong> in otherwise healthy adults. When pandemic flu threatened, governments extrapolated: if it shortens symptoms, it must prevent complications. If it works in healthy adults, it must work in high-risk patients.",
        followup: "Neither extrapolation was supported. Trials in <strong>high-risk patients</strong> (the ones who actually need protection) showed no benefit. Trials measuring <strong>hospitalizations and complications</strong> (the outcomes that matter) were never conducted‚Äîor never published. The ¬£473 million UK stockpile was based on indirect evidence: wrong population (healthy, not high-risk), wrong outcome (symptoms, not complications). The Cochrane review downgraded certainty for both types of indirectness."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üè•", title: "Scenario: l'estrapolazione della popolazione",
        xp: 25,
        scenario: "Un trattamento mostra benefici negli studi condotti su pazienti di et√† compresa tra 18-65 senza comorbidit√†. Le vostre linee guida si rivolgono ai residenti anziani delle case di cura con comorbidit√† multiple. Il trattamento ha ragioni biologicamente plausibili per funzionare in modo diverso negli anziani (metabolismo alterato, interazioni farmacologiche).",
        question: "Dovresti effettuare un downgrade per motivi indiretti?",
        options: [
          { letter: "A", text: "No‚Äîage alone doesn't require downgrading", correct: false },
          { letter: "B", text: "Yes‚Äîbiological reasons for different effects in target population require downgrading", correct: true },
          { letter: "C", text: "Only if the elderly show different baseline risk", correct: false },
          { letter: "D", text: "Utilizzare invece l'analisi dei sottogruppi degli studi originali", correct: false }
        ],
        feedback: {
          correct: "Correct! When there are biological reasons to expect different effects in the target population, downgrade for indirectness. Tamiflu worked in healthy adults but the question was about sick elderly patients‚Äîa population with very different biology. Extrapolation across populations with different biology requires downgrading.",
          incorrect: "Population indirectness applies when the trial population differs meaningfully from the guideline population, especially when there are biological reasons to expect different effects. Elderly with comorbidities may metabolize drugs differently, have drug interactions, and have different risk-benefit profiles."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Il Torcetrapib Tragedia", title: "$800 Million Buried in 82 Days",
        text: "Pfizer's torcetrapib was the most expensive drug development in history‚Äî<strong>$800 million</strong> over 15 years. It dramatically raised HDL cholesterol (the 'good' cholesterol) by 72%. The logic was irresistible: low HDL causes heart disease ‚Üí raising HDL should prevent it. Phase 2 trials showed perfect surrogate outcomes. Pfizer began building manufacturing plants before Phase 3 completed.",
        followup: "The ILLUMINATE trial enrolled <strong>15,067 patients</strong>. After just 82 days, the Data Safety Monitoring Board stopped the trial. Torcetrapib increased death by <strong>58%</strong> and cardiovascular events by 25%. The drug that perfectly improved HDL was killing patients. Pfizer's stock dropped $21 billion in one day. The entire HDL-raising hypothesis‚Äîbuilt on decades of surrogate evidence‚Äîcollapsed. No HDL-raising drug has ever prevented cardiovascular events. Surrogate perfection masked clinical catastrophe."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíî", title: "Scenario: il surrogato perfetto",
        xp: 25,
        scenario: "Un nuovo farmaco aumenta il colesterolo HDL dell'80%, pi√π di qualsiasi agente precedente. L'azienda sostiene: 'Abbiamo dimostrato che l'HDL protegge in modo causale dalle malattie cardiache. Questo farmaco salver√† milioni di vite.\" Richiedono un'approvazione accelerata basata solo sul miglioramento dell'HDL.",
        question: "Based on the torcetrapib experience, what certainty applies to cardiovascular benefit?",
        options: [
          { letter: "A", text: "HIGH‚ÄîHDL is a validated causal risk factor", correct: false },
          { letter: "B", text: "MODERATE‚Äîstrong mechanistic support warrants some confidence", correct: false },
          { letter: "C", text: "LOW to VERY LOW‚ÄîHDL-raising has consistently failed to translate to outcomes", correct: true },
          { letter: "D", text: "Cannot rate until mechanism is fully understood", correct: false }
        ],
        feedback: {
          correct: "Correct! Torcetrapib, dalcetrapib, evacetrapib‚Äîevery HDL-raising drug has failed to prevent cardiovascular events despite dramatic surrogate improvement. The entire drug class teaches us: manipulating a surrogate doesn't guarantee clinical benefit. Evidence from this class requires serious downgrading for indirectness.",
          incorrect: "Numerosi farmaci che aumentano l‚ÄôHDL hanno mostrato un notevole miglioramento surrogato senza alcun beneficio cardiovascolare (o danno reale). Questa classe di farmaci ha definitivamente dimostrato che la manipolazione dell'HDL non si traduce in risultati. La relazione surrogata non regge quando viene manipolata farmacologicamente."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "L'inversione dell'eritropoietina", title: "When Better Blood Was Worse",
        text: "I pazienti affetti da cancro con anemia si sentono malissimo: stanchezza, debolezza, mancanza di respiro. Gli agenti stimolanti l‚Äôeritropoietina (ESA) hanno aumentato l‚Äôemoglobina e fatto sentire meglio i pazienti. La qualit√† della vita √® migliorata. La FDA ha approvato gli ESA per l‚Äôanemia correlata al cancro. Gli oncologi li prescrivono ampiamente.",
        followup: "Then meta-analyses examining <strong>mortality</strong> emerged. Despite improving hemoglobin (surrogate) and quality of life, ESAs increased <strong>death by 10%</strong> and thromboembolic events by 57%. Patients felt better while dying faster. The FDA added a black box warning. ESA use plummeted. The lesson: even quality-of-life improvements can coexist with mortality harm. Surrogates that patients can feel aren't necessarily safer surrogates."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü©∏", title: "Scenario: The Quality of Life Surrogate",
        xp: 25,
        scenario: "Un trattamento migliora notevolmente un surrogato del sintomo: i pazienti si sentono molto meglio, l'energia migliora, la funzione quotidiana aumenta. I punteggi sulla qualit√† della vita migliorano del 40%. Non esistono dati sulla mortalit√†. L'azienda sostiene che si tratta di \"prove incentrate sul paziente\" che dovrebbero ricevere un'elevata certezza.",
        question: "What certainty applies to net clinical benefit?",
        options: [
          { letter: "A", text: "HIGH‚Äîpatient-reported outcomes matter most", correct: false },
          { letter: "B", text: "MODERATE‚Äîquality of life is a valid outcome", correct: false },
          { letter: "C", text: "LOW‚Äîimproved symptoms can coexist with mortality harm; need outcome data", correct: true },
          { letter: "D", text: "Dipende dalla condizione specifica", correct: false }
        ],
        feedback: {
          correct: "Esatto! Gli ESA hanno migliorato la qualit√† della vita aumentando la mortalit√† del 10%. Sentirsi meglio non √® la stessa cosa che essere migliori. Il miglioramento dei sintomi pu√≤ mascherare un danno alla sopravvivenza. Il GRADE richiede un declassamento indiretto quando i dati sulla mortalit√†/danno grave sono assenti, anche con esiti positivi dei sintomi.",
          incorrect: "L'esperienza dell'ESA dimostra che i pazienti possono sentirsi notevolmente meglio mentre muoiono pi√π velocemente. Il miglioramento della qualit√† della vita √® reale ma non garantisce un beneficio netto. Senza dati sulla mortalit√† e sugli eventi avversi gravi, la certezza deve rimanere bassa indipendentemente dal miglioramento dei sintomi."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Four Types of Indirectness",
        items: [
          "Population ‚Äî Trial patients differ from guideline patients",
          "Intervention ‚Äî Trial intervention differs from recommendation",
          "Confronto: il confronto degli studi differisce dal quesito clinico",
          "Outcome ‚Äî Trial measures surrogates instead of patient-important outcomes"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Perch√© i farmaci antiaritmici CAST hanno ucciso 50.000 persone nonostante l'evidenza perfetta di soppressione dell'aritmia?",
        options: [
          { text: "Gli studi sono stati fraudolento", correct: false },
          { text: "Il surrogato (soppressione dell'aritmia) non ha previsto l'esito (morte)", correct: true },
          { text: "Doctors used the drugs incorrectly", correct: false },
          { text: "La popolazione di pazienti era diversa dagli studi", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. The evidence for arrhythmia suppression was impeccable. The drugs did exactly what they were supposed to do on ECG. But suppressing arrhythmias didn't prevent death‚Äîit caused it through different mechanisms. This is indirectness for outcome: measuring surrogates instead of patient-important endpoints.",
          incorrect: "The trials were well-conducted. The drugs worked perfectly for their intended purpose (suppressing arrhythmias). The problem was indirectness: arrhythmia suppression (the measured outcome) didn't predict mortality (the outcome that matters). Surrogate outcomes can mislead even when evidence is methodologically perfect."
        }
      }}
    ]
  },
  {
    id: 6, title: "Imprecision", subtitle: "Dati insufficienti", xp: 150,
    slides: [
      { type: "title", theme: "dark", content: { title: "Imprecision", subtitle: "Il quarto dominio: ne abbiamo abbastanza dati?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand why wide confidence intervals undermine certainty",
          "Apply the 'Optimal Information Size' concept",
          "Recognize when 95% CIs cross clinical decision thresholds",
          "Decide when to downgrade for imprecision"
        ],
        tip: "Statistical significance is not enough‚Äîconfidence intervals must be clinically narrow."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "PROWESS Mirage", title: "When 1,690 Deaths Weren't Enough",
        text: "In 2001, Eli Lilly's drotrecogin alfa (Xigris) was approved for severe sepsis based on the PROWESS trial. The trial showed <strong>6.1% absolute mortality reduction</strong>‚Äîfrom 30.8% to 24.7%. The FDA approved it despite concerns. Cost: $6,800 per treatment. Lilly projected billions in revenue.",
        followup: "Then came the confidence interval analysis. The 95% CI for mortality reduction ranged from <strong>1.9% to 10.4%</strong>. The benefit might be huge (10.4%) or clinically marginal (1.9%). With a drug this expensive and risky (increased bleeding), that uncertainty mattered. Subsequent trials failed to replicate PROWESS. The ADDRESS trial in less severe sepsis showed <strong>no benefit</strong>. The PROWESS-SHOCK trial confirmed <strong>no mortality benefit</strong> even in severe sepsis. In 2011, Lilly withdrew Xigris worldwide. A decade of use, billions spent, and the imprecision had warned us from the start."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìê", title: "Scenario: The Wide Confidence Interval",
        xp: 25,
        scenario: "A trial shows a new treatment reduces mortality from 20% to 14%‚Äîa 6% absolute reduction (RR 0.70, p=0.04). However, the 95% CI for absolute risk reduction is 0.5% to 11.5%. The lower bound (0.5%) is below your minimum clinically important difference of 2%.",
        question: "Dovresti eseguire il downgrade per imprecisione?",
        options: [
          { letter: "A", text: "No, il risultato √® statisticamente significativo", correct: false },
          { letter: "B", text: "No‚Äîthe point estimate shows clinically meaningful benefit", correct: false },
          { letter: "C", text: "Yes‚Äîthe CI includes clinically unimportant effects", correct: true },
          { letter: "D", text: "S√¨, l'IC include il danno", correct: false }
        ],
        feedback: {
          correct: "Esatto! La significativit√† statistica non garantisce la precisione clinica. Se l'effetto reale potesse essere pari allo 0,5% (al di sotto della differenza minima importante), non puoi raccomandare con sicurezza il trattamento. GRADE richiede il declassamento quando gli IC superano le soglie delle decisioni cliniche, non solo quelle nulle.",
          incorrect: "Il limite inferiore dell'IC (0,5%) scende al di sotto della differenza minima clinicamente importante (2%). Ci√≤ significa che l‚Äôeffetto reale potrebbe essere troppo piccolo per giustificare i costi/rischi del trattamento. La significativit√† statistica non √® sufficiente: gli IC devono escludere effetti clinicamente non importanti per avere un'elevata certezza."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "La dimensione ottimale delle informazioni", title: "Why Sample Size Matters for Certainty",
        text: "Consider a simple thought experiment: You flip a coin 4 times and get 3 heads (75%). Would you bet your house that the coin is biased? Now flip 1,000 times and get 750 heads. Same proportion‚Äîbut utterly different certainty.",
        followup: "GRADE uses the <strong>Optimal Information Size (OIS)</strong> concept. This asks: 'How many events would a single adequately-powered trial need to reliably detect this effect?' If your meta-analysis has fewer events than the OIS, you're in the position of the person who flipped 4 coins‚Äîthe proportion might be right, but you don't have enough data to be confident. For mortality outcomes, OIS is typically <strong>200-400 events</strong>. Many celebrated meta-analyses have far fewer."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¢", title: "Scenario: la piccola meta-analisi",
        xp: 25,
        scenario: "A meta-analysis of 8 RCTs (total n=1,200) shows a treatment prevents death with RR 0.65 (95% CI 0.45-0.95). The total number of deaths across all trials is 87. The pooled estimate is statistically significant. Your OIS calculation suggests 300 events would be needed.",
        question: "Dovresti eseguire il downgrade per imprecisione?",
        options: [
          { letter: "A", text: "No‚Äîstatistical significance means adequate precision", correct: false },
          { letter: "B", text: "No‚Äî8 RCTs provide adequate power through meta-analysis", correct: false },
          { letter: "C", text: "Yes‚Äî87 events is well below the OIS of 300", correct: true },
          { letter: "D", text: "Solo se l'IC incrocia 1.0", correct: false }
        ],
        feedback: {
          correct: "Esatto! 87 eventi contro 300 OIS significa che abbiamo meno del 30% delle informazioni necessarie. La stima potrebbe essere corretta, ma siamo nel territorio del ‚Äúpiccolo campione‚Äù dove la variazione casuale pu√≤ produrre effetti apparentemente drammatici ma inaffidabili. GRADE richiede il downgrade quando gli eventi sono molto al di sotto dell'OIS.",
          incorrect: "La meta-analisi non crea magicamente informazioni. 8 prove piccole con 87 eventi totali non equivalgono a una prova grande con 300 eventi. La significativit√† statistica √® probabilmente fragile: in ogni caso, alcuni eventi potrebbero cambiare la conclusione. L'OIS fornisce un controllo reale sull'adeguatezza del campione."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "L'inversione dell'amido idrossietilico", title: "When 10,000 Patients Weren't Enough... Then Were",
        text: "Hydroxyethyl starch (HES) fluids were used for decades in critically ill patients. Early meta-analyses with few events showed possible benefit. Then came the large trials: <strong>6S trial (798 patients)</strong>, <strong>CHEST trial (7,000 patients)</strong>, <strong>CRISTAL trial (2,857 patients)</strong>.",
        followup: "The large trials showed HES <strong>increased mortality and kidney failure</strong>. The earlier 'positive' evidence had been imprecise‚Äîconfidence intervals that allowed for benefit also allowed for the substantial harm that large trials eventually detected. The European Medicines Agency suspended HES for critical illness. Imprecise evidence had allowed a harmful intervention to persist for years."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Scenario: The Borderline Mortality Signal",
        xp: 25,
        scenario: "Una meta-analisi mostra un RR per la morte di 1,25 (IC 95% 0,98-1,60) con un trattamento. Il risultato \"tende al danno\" ma non √® statisticamente significativo. Le linee guida devono decidere se raccomandare questo trattamento per una condizione non fatale in cui esistono alternative.",
        question: "How should imprecision affect your recommendation?",
        options: [
          { letter: "A", text: "Il trattamento √® sicuro: l'IC include 1,0", correct: false },
          { letter: "B", text: "The treatment is harmful‚Äîpoint estimate shows 25% increase", correct: false },
          { letter: "C", text: "Grave incertezza sul danno: CI coerente con un aumento della mortalit√† fino al 60%", correct: true },
          { letter: "D", text: "Need more trials before any conclusion", correct: false }
        ],
        feedback: {
          correct: "Correct! The upper bound (1.60) represents a 60% mortality increase. For a non-fatal condition with alternatives, that possibility should drive decision-making. 'Not statistically significant' doesn't mean safe‚Äîit means we can't rule out substantial harm. GRADE incorporates the entire CI, not just p-values.",
          incorrect: "Il limite superiore dell'IC di 1,60 significa che non possiamo escludere Aumento della mortalit√† del 60%. Per un trattamento che affronta una condizione non fatale in cui esistono alternative, questa incertezza sul danno grave dovrebbe dominare la decisione. Non significativit√† statistica ‚â† sicurezza."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "L'indice di fragilit√†",
        subtitle: "How stable is statistical significance?",
        text: "The fragility index asks: 'How many patients would need to have had a different outcome to make this result non-significant?' A fragility index of 3 means if just 3 patients had different outcomes, the p-value would cross 0.05. Many published 'significant' findings have fragility indices under 10.",
        highlight: "Uno studio con indice di fragilit√† pari a 5 significa che il risultato \"significativo\" dipende da meno pazienti di quelli seduti nella sala d'attesa del tuo ufficio."
      }},
      { type: "story", theme: "dark", content: {
        label: "L'acido tranexamico Trionfo", title: "When Precision Demanded 20,000 Patients",
        text: "Could tranexamic acid (TXA) reduce death from bleeding in trauma? Early trials were suggestive but imprecise. The <strong>CRASH-2 trial</strong> took a different approach: enroll enough patients to get a precise answer.",
        followup: "<strong>20,211 patients</strong> across 274 hospitals in 40 countries. Result: TXA reduced death from bleeding from 5.7% to 4.9%‚Äîa 0.8% absolute reduction. The 95% CI was <strong>0.3% to 1.3%</strong>. Finally, precision: the entire CI showed clinically meaningful benefit. The WHO added TXA to its Essential Medicines List. The precision wasn't just scientific‚Äîit changed global policy because decision-makers could trust the narrow bounds."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚úì", title: "Scenario: The Precise But Small Effect",
        xp: 25,
        scenario: "A mega-trial (n=40,000) shows a treatment reduces mortality with RR 0.95 (95% CI 0.91-0.99). The result is statistically significant and the CI is narrow. However, the absolute risk reduction is 0.3% (NNT = 333). Your minimum clinically important difference for this outcome is 0.2%.",
        question: "Dovresti eseguire il downgrade per imprecisione?",
        options: [
          { letter: "A", text: "Yes‚Äîthe effect is too small to matter clinically", correct: false },
          { letter: "B", text: "No‚Äîthe narrow CI excludes clinically unimportant effects", correct: true },
          { letter: "C", text: "Yes‚ÄîNNT of 333 suggests imprecision", correct: false },
          { letter: "D", text: "Cannot determine without knowing the OIS", correct: false }
        ],
        feedback: {
          correct: "Correct! The entire CI (0.91-0.99) lies below 1.0, and the corresponding absolute effects (0.1%-0.5%) are all above your minimum important difference of 0.2%. Small but precise effects that meet the clinical threshold don't require downgrading for imprecision. The issue is clinical judgment about whether the effect justifies intervention.",
          incorrect: "L'imprecisione riguarda gli intervalli di confidenza, non la dimensione dell'effetto. Un effetto piccolo ma stimato con precisione che esclude valori clinicamente non importanti non √® impreciso: √® semplicemente piccolo. Se una riduzione assoluta dello 0,3% giustifichi il trattamento √® un giudizio di valore, non una questione di precisione."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "La controversia su JUPITER", title: "When 17,802 Patients Still Weren't Enough",
        text: "The JUPITER trial enrolled <strong>17,802 patients</strong> to test rosuvastatin for primary prevention. After just 1.9 years (planned: 5 years), it was stopped early for 'overwhelming benefit.' Heart attacks were reduced by 54%! Headlines celebrated. Rosuvastatin prescriptions soared.",
        followup: "But critics noticed problems. Only <strong>68 heart attacks</strong> total across both groups‚Äîfragility index of just 4. The wide confidence intervals (0.29-0.73) reflected genuine uncertainty. Early stopping inflates effect sizes by 30% on average. And absolute risk reduction was just <strong>0.35%</strong> over 1.9 years‚ÄîNNT of 286. A 'landmark' trial with thousands of patients still had imprecision concerns because it was stopped before enough events accumulated. Large n doesn't guarantee precision when event rates are low."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚èπÔ∏è", title: "Scenario: la sperimentazione interrotta in anticipo",
        xp: 25,
        scenario: "A large trial (n=10,000) is stopped early after 2 years (planned: 5) for 'overwhelming efficacy.' The treatment shows 50% relative risk reduction. However, only 45 total events occurred, and the original planned stopping boundary was crossed by just 2 events.",
        question: "How should early stopping affect certainty assessment?",
        options: [
          { letter: "A", text: "No concern‚Äîlarge sample size ensures precision", correct: false },
          { letter: "B", text: "Declassamento per imprecisione: l'interruzione anticipata gonfia gli effetti e crea fragilit√† risultati", correct: true },
          { letter: "C", text: "Upgrade certainty‚Äîstopping early proves the effect is large", correct: false },
          { letter: "D", text: "Neutral‚Äîmonitoring rules are pre-specified", correct: false }
        ],
        feedback: {
          correct: "Correct! Early stopping typically inflates effect sizes by 30%. With only 45 events and crossing the boundary by 2, this finding is extremely fragile. Large n doesn't help when event rates are low‚Äîyou need enough events, not just patients. GRADE recommends downgrading for trials stopped early with few events.",
          incorrect: "Gli studi si sono interrotti precocemente e hanno sovrastimato sistematicamente gli effetti. Con 45 eventi e un indice di fragilit√† di ~2, la riduzione del 50% scomparirebbe se solo 2 pazienti avessero esiti diversi. Il campione di grandi dimensioni √® irrilevante: sono gli eventi che determinano la precisione."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "La lezione ISIS-4", title: "Quando 58.000 pazienti hanno risposto alla domanda",
        text: "After GISSI-2 suggested magnesium might reduce mortality in heart attack patients, smaller trials showed inconsistent results. The <strong>ISIS-4</strong> trial was designed to end the debate: <strong>58,050 patients</strong>, the largest heart attack trial ever. If magnesium worked, this trial would prove it.",
        followup: "Result: magnesium showed <strong>no benefit</strong> (mortality 7.64% vs. 7.24%, NS). The pooled meta-analysis before ISIS-4 had shown significant benefit‚Äîbut was driven by small trials with imprecise estimates. When finally tested with adequate precision, the effect vanished. This pattern‚Äîdramatic effects in small trials, null effects in large trials‚Äîis so common it has a name: 'the winner's curse.' Small trials select for extreme results; large trials reveal reality."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üé≤", title: "Scenario: Small Trial Meta-Analysis vs. Large Trial",
        xp: 25,
        scenario: "A meta-analysis of 15 small trials (total n=2,000, 180 events) shows significant mortality benefit (RR 0.65, p=0.001). A single large trial (n=15,000, 2,100 events) shows no benefit (RR 0.98, p=0.61). The meta-analysis was published first.",
        question: "Come dovresti valutare questi risultati contrastanti?",
        options: [
          { letter: "A", text: "Average them‚Äîmore trials means more evidence", correct: false },
          { letter: "B", text: "Prefer the meta-analysis‚Äî15 trials beat 1 trial", correct: false },
          { letter: "C", text: "Preferisco lo studio di grandi dimensioni: ha 10 volte pi√π eventi e precisione", correct: true },
          { letter: "D", text: "Dichiara le prove inconcludenti", correct: false }
        ],
        feedback: {
          correct: "Corretto! 2.100 eventi contro 180 eventi significano che lo studio pi√π ampio ha circa 12 volte pi√π informazioni. Piccole meta-analisi sperimentali sono soggette a bias di pubblicazione e alla maledizione del vincitore. Quando uno studio ampio e adeguatamente strutturato contraddice meta-analisi di studi piccoli, lo studio pi√π ampio di solito rivela la verit√†.",
          incorrect: "ISIS-4 taught this lesson. Small trials showed magnesium benefit; the 58,000-patient trial showed nothing. Events determine precision, not number of trials. Publication bias and random variation create false signals in small trial meta-analyses that large trials correct."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Imprecision Assessment Checklist",
        items: [
          "Does the 95% CI cross clinically important thresholds?",
          "L'IC incrocia sia i benefici che i danni?",
          "Il numero totale di eventi √® inferiore alla dimensione ottimale delle informazioni?",
          "Qual √® l'indice di fragilit√† per i principali risultati?",
          "Would the upper or lower bound change clinical decision-making?"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Why does GRADE require downgrading when confidence intervals cross 'clinical decision thresholds' even if statistically significant?",
        options: [
          { text: "Le convenzioni statistiche sono arbitrarie", correct: false },
          { text: "The true effect might be too small (or too harmful) to justify treatment", correct: true },
          { text: "P-values don't account for sample size", correct: false },
          { text: "Confidence intervals are more accurate than p-values", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Esattamente. Se un trattamento riduce ‚Äúsignificativamente‚Äù la mortalit√† ma l‚ÄôIC include effetti troppo piccoli per giustificare il rapporto costo/rischio ‚Äì o include danni sostanziali ‚Äì non possiamo raccomandarlo con sicurezza. GRADE valuta la precisione rispetto alle soglie cliniche, non alle convenzioni statistiche.",
          incorrect: "Le decisioni cliniche richiedono di sapere se l'effetto reale √® abbastanza grande da essere importante. Un risultato statisticamente significativo con un CI che va da \"banalmente utile\" a \"sostanzialmente dannoso\" non guida il trattamento. GRADE utilizza soglie cliniche perch√© questo √® ci√≤ che richiedono le decisioni."
        }
      }}
    ]
  },
  {
    id: 7, title: "Publication Bias", subtitle: "Le prove invisibili", xp: 160,
    slides: [
      { type: "title", theme: "red-bg", content: { title: "Publication Bias", subtitle: "Il quinto dominio: quali prove non ci sono mai arrivate?" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Comprendere come gli studi negativi scompaiono dalla letteratura",
          "Interpret funnel plots and their limitations",
          "Recognize when publication bias likely distorts evidence",
          "Decide when to downgrade certainty for publication bias"
        ],
        tip: "Le prove pi√π pericolose sono le prove che non hai mai vedere."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "L'inganno della paroxetina", title: "GlaxoSmithKline's Hidden Children",
        text: "In the early 2000s, GSK marketed paroxetine (Paxil) for adolescent depression. The published evidence looked convincing. Study 329, published in the <em>Journal of the American Academy of Child and Adolescent Psychiatry</em>, reported paroxetine was <strong>'generally well tolerated and effective.'</strong> Thousands of teenagers were prescribed the drug.",
        followup: "Then lawsuits forced GSK to release internal documents. Study 329 had actually shown paroxetine was <strong>no better than placebo</strong> and increased suicidal behavior. GSK had conducted other trials‚Äîalso negative‚Äîthat were never published. The published paper had been ghost-written by a medical communications company. When all studies were combined, the truth emerged: paroxetine didn't work for teen depression and was dangerous. The published literature had been systematically manipulated. Publication bias wasn't passive‚Äîit was manufactured."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìö", title: "Scenario: la letteratura completamente positiva",
        xp: 25,
        scenario: "Una meta-analisi comprende 12 studi finanziati dall'industria su un nuovo antidepressivo, tutti che mostrano benefici. Il grafico a imbuto appare simmetrico. Un collega osserva che i registri della FDA mostrano che la societ√† ha condotto 8 ulteriori studi che non sono mai stati pubblicati. Non puoi accedere ai dati non pubblicati.",
        question: "Dovresti eseguire il downgrade per bias di pubblicazione?",
        options: [
          { letter: "A", text: "No, il grafico a imbuto √® simmetrico", correct: false },
          { letter: "B", text: "No, possiamo solo giudicare le prove esistenti", correct: false },
          { letter: "C", text: "Yes‚Äîdocumented unpublished trials suggest selective reporting", correct: true },
          { letter: "D", text: "Richiedi i dati prima di decidere", correct: false }
        ],
        feedback: {
          correct: "Correct! The funnel plot only shows published studies‚Äîit can't detect missing studies. Knowing that 8 unpublished trials exist is strong evidence of publication bias. Paroxetine's symmetric funnel plot concealed hidden negative trials. GRADE downgrades when there's direct evidence of unpublished studies.",
          incorrect: "I grafici a imbuto mostrano solo ci√≤ che √® pubblicato. Se gli studi negativi vengono sistematicamente soppressi (come con la paroxetina), l‚Äôimbuto pu√≤ apparire perfetto nascondendo prove cruciali. I registri della FDA che mostrano studi non pubblicati sono prova diretta di bias di pubblicazione."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Il blocco dell'oseltamivir", title: "Five Years to See the Truth",
        text: "The Cochrane Collaboration spent <strong>five years</strong> fighting Roche for Tamiflu (oseltamivir) data. Published trials showed reduced complications. Governments stockpiled billions of dollars worth of the drug. But Cochrane noticed discrepancies: study reports didn't match clinical study reports.",
        followup: "When Roche finally released the data in 2013, the missing <strong>60% of patient data</strong> revealed the truth. Published trials had reported 'complications' without proper definitions. Unpublished data showed adverse events were underreported. The updated Cochrane review: Tamiflu reduced symptoms by less than a day and had <strong>no proven effect on hospitalization or complications</strong>. Five years. Billions of dollars. And the published literature had been a carefully curated selection."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Scenario: l'imbuto asimmetrico",
        xp: 25,
        scenario: "A funnel plot shows clear asymmetry‚Äîsmall studies cluster toward positive effects while negative small studies are absent. Egger's test is statistically significant (p=0.01). The meta-analysis includes 25 trials with a pooled OR of 0.65 (significant benefit).",
        question: "Come dovrebbe influire questo sul tuo livello di certezza?",
        options: [
          { letter: "A", text: "No effect‚ÄîEgger's test has poor specificity", correct: false },
          { letter: "B", text: "Downgrade one level‚Äîasymmetry suggests missing negative small studies", correct: true },
          { letter: "C", text: "Escludere studi di piccole dimensioni e rianalizzare", correct: false },
          { letter: "D", text: "Asymmetry could be small-study effects, not publication bias", correct: false }
        ],
        feedback: {
          correct: "Correct! Significant funnel asymmetry with missing negative small studies is classic publication bias. Small negative studies are less likely to be published than small positive ones. Egger's test p=0.01 supports genuine asymmetry. GRADE requires downgrading when funnel asymmetry is clearly present.",
          incorrect: "While asymmetry has multiple causes, missing negative small studies is the most common pattern. The scenario describes classic publication bias: small positive studies published, small negative studies missing. This requires downgrading even if the exact cause is uncertain."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Lo scandalo della reboxetina", title: "74% of Data Hidden",
        text: "Reboxetine, an antidepressant approved in Europe, had <strong>74% of patient data</strong> from clinical trials never published. The published literature showed the drug worked. Regulatory agencies approved it. Doctors prescribed it to thousands of patients.",
        followup: "German researchers obtained the unpublished data through freedom of information requests. When all data was combined, reboxetine was <strong>no better than placebo</strong> and caused more side effects than other antidepressants. The published literature‚Äîbased on only 26% of the data‚Äîhad created a complete fiction. A drug that didn't work and caused harm had been sold for years because three-quarters of the evidence was invisible."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üóÉÔ∏è", title: "Scenario: il divario nel registro",
        xp: 25,
        scenario: "Stai valutando le sperimentazioni di un farmaco antitumorale. ClinicalTrials.gov mostra che 15 studi sono stati registrati e completati tra il 2010 e il 2018. La tua ricerca sistematica trova solo 9 articoli pubblicati. I 6 studi non pubblicati erano tutti pi√π piccoli di quelli pubblicati.",
        question: "Cosa dovresti concludere riguardo ai bias di pubblicazione?",
        options: [
          { letter: "A", text: "Nessun bias: gli studi pi√π piccoli sono spesso studi pilota", correct: false },
          { letter: "B", text: "Non sono chiari: non conosciamo i risultati degli studi non pubblicati", correct: false },
          { letter: "C", text: "High likelihood of bias‚Äî40% of completed trials unpublished, all smaller ones", correct: true },
          { letter: "D", text: "Request unpublished results before rating", correct: false }
        ],
        feedback: {
          correct: "Correct! 40% unpublished rate‚Äîand specifically the smaller trials‚Äîis a red flag. Small trials showing positive results get published; small trials showing nothing often don't. This pattern inflates pooled estimates. GRADE recognizes registry-publication gaps as strong evidence of publication bias.",
          incorrect: "Sei dei 15 studi completati (40%) non sono mai stati pubblicati e tutti erano studi pi√π piccoli. Questo √® esattamente lo schema che gonfia le meta-analisi: i piccoli studi negativi scompaiono. Non possiamo aspettare indefinitamente dati non pubblicati: dobbiamo riconoscere che esiste un pregiudizio."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "La scala delle prove nascoste",
        stats: [
          { value: "50%", label: "Trials never published" },
          { value: "74%", label: "Dati nascosti sulla reboxetina" },
          { value: "60%", label: "Dati sul Tamiflu non pubblicati" },
          { value: "31%", label: "Outcomes switched" }
        ],
        caption: "La letteratura pubblicata rappresenta un selezione curata, non prove complete."
      }},
      { type: "concept", theme: "dark", content: {
        title: "Why Funnel Plots Aren't Enough",
        subtitle: "Rilevare l'non rilevabile",
        text: "Funnel plots can only show what's published. They cannot detect:<br>‚Ä¢ Entire drugs that failed in trials and were never developed further<br>‚Ä¢ Studies with outcome switching (positive outcomes published, negative ones hidden)<br>‚Ä¢ Industry studies kept confidential<br>‚Ä¢ Studies published in inaccessible journals",
        highlight: "When publication bias is well-executed, it leaves no visible trace in the published literature."
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Publication Bias Red Flags",
        items: [
          "All or most trials industry-funded",
          "Trial registries show unpublished completed trials",
          "Asimmetria del diagramma a imbuto con piccoli studi negativi mancanti",
          "Outcomes in publications differ from registered protocols",
          "Large effects in meta-analysis contradicted by single large trial"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Perch√© i bias di pubblicazione con paroxetina per la depressione adolescenziale non sono stati rilevati per anni?",
        options: [
          { text: "Gli studi erano ben condotto", correct: false },
          { text: "Gli studi negativi sono stati nascosti e lo studio positivo √® stato scritto in modo fantasma per travisare i risultati", correct: true },
          { text: "The drug genuinely worked in some patients", correct: false },
          { text: "Le agenzie di regolamentazione non hanno esaminato i dati", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Esattamente. GSK nascose gli studi negativi e assunse una societ√† di comunicazioni mediche per scrivere lo Studio 329 in un modo che facesse sembrare efficace la paroxetina. La parzialit√† della pubblicazione era deliberata e sistematica, visibile solo quando le cause legali obbligavano alla divulgazione.",
          incorrect: "L'inganno era attivo, non passivo. GSK sapeva che la paroxetina non funzionava per la depressione adolescenziale e per l'aumento del comportamento suicidario. Hanno seppellito i processi negativi e hanno travisato quello pubblicato. I metodi di rilevamento tradizionali non sono riusciti a trovare ci√≤ che era deliberatamente nascosto."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "L'illusione antidepressiva", title: "Turner's 94 Trial Revelation",
        text: "In 2008, Dr. Erick Turner at the FDA did something unprecedented: he compared <strong>74 FDA-registered antidepressant trials</strong> to what was actually published. The FDA had seen all trials‚Äîpositive and negative. The literature had seen a carefully curated selection.",
        followup: "The results were damning. Of 38 positive trials, <strong>37 were published</strong>. Of 36 negative or questionable trials, only <strong>3 were published as negative</strong>‚Äî22 were never published, and 11 were published but 'spun' to appear positive. The published literature showed antidepressants were effective in 94% of trials. The FDA data showed 51%. Effect sizes in publications were <strong>32% larger</strong> than reality. An entire drug class had its efficacy inflated by systematic publication bias."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Scenario: la letteratura selettiva",
        xp: 25,
        scenario: "You're assessing antidepressants for a guideline. The published literature shows 12 of 15 trials are positive. However, you discover FDA databases listing 8 additional completed trials that were never published. The published effect size is d=0.50.",
        question: "Come dovresti adattare la tua valutazione della certezza?",
        options: [
          { letter: "A", text: "Use only published trials‚Äîunpublished data isn't peer-reviewed", correct: false },
          { letter: "B", text: "Downgrade significantly‚Äî8 unpublished trials likely changes the effect size substantially", correct: true },
          { letter: "C", text: "Assume unpublished trials showed similar results", correct: false },
          { letter: "D", text: "Request unpublished data before making any assessment", correct: false }
        ],
        feedback: {
          correct: "Esatto! L'analisi di Turner ha mostrato che le dimensioni degli effetti pubblicati erano gonfiate del 32%. Otto studi non pubblicati su 23 totali (35% nascosti) indicano che la stima dell'effetto √® probabilmente sostanzialmente distorta. Downgrade per bias di pubblicazione e nota che l'effetto reale √® probabilmente inferiore alle stime pubblicate.",
          incorrect: "La letteratura sugli antidepressivi ha mostrato il 94% di studi positivi nelle pubblicazioni contro il 51% nei dati della FDA. Gli studi non pubblicati sono sistematicamente negativi. Supporre che siano simili agli studi pubblicati contraddice decenni di prove sui modelli di bias di pubblicazione."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Il disastro del RECORD", title: "When a Safety Study Hid Safety Signals",
        text: "After Avandia's cardiovascular concerns emerged, GSK designed RECORD‚Äîa 'cardiovascular safety study' of rosiglitazone. The study enrolled <strong>4,447 patients</strong> and ran for 5+ years. It was specifically designed to assess cardiovascular safety. The published conclusion: 'Rosiglitazone did not significantly increase cardiovascular risk.'",
        followup: "An FDA re-analysis told a different story. RECORD had serious adjudication problems‚Äî<strong>35% of potential cardiovascular events weren't properly evaluated</strong>. Some patients' events were classified as 'non-cardiac' when records suggested otherwise. The study designed to answer the safety question had been conducted in ways that systematically underdetected the very events it was supposed to measure. The publication bias wasn't in what studies were published‚Äîit was in how the study itself was designed and analyzed to produce a publishable 'negative' safety finding."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Scenario: lo studio \"rassicurante\" sulla sicurezza",
        xp: 25,
        scenario: "A drug with suspected harm has a 'definitive' safety study published showing no increased risk. However, you notice: outcomes were adjudicated by company employees, 30% of potential events were excluded as 'protocol deviations,' and the comparison group had higher baseline risk.",
        question: "In che modo queste caratteristiche metodologiche dovrebbero influenzare la tua interpretazione?",
        options: [
          { letter: "A", text: "Accetta il rassicurazione: lo studio √® stato progettato specificamente per la sicurezza", correct: false },
          { letter: "B", text: "Be skeptical‚Äîsystematic bias in outcome ascertainment can hide real signals", correct: true },
          { letter: "C", text: "Partially reassured‚Äîsome bias doesn't eliminate all value", correct: false },
          { letter: "D", text: "Ignora e attendi la replica indipendente", correct: false }
        ],
        feedback: {
          correct: "Corretto! RECORD ci ha insegnato che gli \"studi sulla sicurezza\" possono essere progettati per non individuare danni. Le valutazioni aziendali, le esclusioni selettive e i confronti favorevoli possono sistematicamente sottovalutare gli eventi avversi. Uno studio sulla sicurezza \"negativo\" con queste caratteristiche fornisce una falsa rassicurazione.",
          incorrect: "Uno studio sulla sicurezza progettato e giudicato dall'azienda con il prodotto sospetto presenta evidenti conflitti. Il tasso di mancata valutazione del 35% di RECORD significava che gli eventi non venivano conteggiati correttamente. 'Progettato per la sicurezza' non ha senso se il design consente al danno di sfuggire al rilevamento."
        }
      }}
    ]
  },
  {
    id: 8, title: "Upgrading Factors", subtitle: "When observational evidence earns trust", xp: 140,
    slides: [
      { type: "title", theme: "green-bg", content: { title: "Upgrading Factors", subtitle: "When observation rivals randomization" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Understand the three GRADE upgrading factors",
          "Learn when large effects can overcome confounding",
          "Recognize dose-response gradients as evidence of causation",
          "Apply 'all plausible confounders' reasoning"
        ],
        tip: "Upgrading is rare‚Äîbut sometimes observational evidence is unassailable."
      }},
      { type: "story", theme: "green-bg", content: {
        label: "La prova del fumo", title: "How 30x Risk Silenced Doubt",
        text: "In 1950, Richard Doll and Austin Bradford Hill published their case-control study: smokers had <strong>30 times higher lung cancer rates</strong> than non-smokers. The tobacco industry demanded RCTs‚Äîknowing they were impossible. 'Correlation isn't causation,' they insisted. 'Where's the randomized evidence?'",
        followup: "But the effect size spoke for itself. For confounding to explain a 30-fold increase, some unmeasured factor would need to cause both smoking and lung cancer with extraordinary strength‚Äîand be distributed perfectly across populations, generations, and geographies. No such confounder has ever been found. The evidence was upgraded from LOW to HIGH. GRADE recognizes that some effects are too large for confounding to explain."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìà", title: "Scenario: il grande effetto",
        xp: 25,
        scenario: "Uno studio osservazionale mostra che una procedura chirurgica riduce la mortalit√† dall'80% al 10%, un rischio relativo di 0,125 (87,5% relativo riduzione). Non esistono studi randomizzati perch√© sospendere il trattamento non sarebbe etico dato il notevole beneficio osservato.",
        question: "Questa evidenza dovrebbe essere aggiornata per ottenere un effetto di grandi dimensioni?",
        options: [
          { letter: "A", text: "No: l'evidenza osservativa non pu√≤ essere aggiornata", correct: false },
          { letter: "B", text: "Yes‚ÄîRR 0.125 is so large that confounding alone is implausible", correct: true },
          { letter: "C", text: "Solo se lo studio √® ben progettati", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.125 (or 8-fold relative reduction) is in the range where confounding alone is implausible. No unmeasured confounder could realistically reduce mortality from 80% to 10%. GRADE upgrades for large effects when RR < 0.5 or > 2, with additional upgrading for very large effects (RR < 0.2 or > 5).",
          incorrect: "Effetti cos√¨ grandi sono essenzialmente a prova di RCT. Nessun fattore confondente potrebbe spiegare in modo plausibile una riduzione relativa dell‚Äô87,5%. I paracadute non sono mai stati testati in studi randomizzati, ma non dubitiamo che funzionino: la dimensione dell'effetto √® evidente. GRADE consente l'aggiornamento per effetti troppo grandi per essere confondenti da spiegare."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "La scoperta dei folati", title: "Neural Tube Defects Prevented",
        text: "Negli anni '80, studi osservazionali suggerivano che l'integrazione di folati preveniva i difetti del tubo neurale (NTD) come la spina bifida. Ma come si pu√≤ esserne certi? Sembrava inevitabile creare confusione: le donne che assumono vitamine sono probabilmente pi√π sane sotto molti aspetti.",
        followup: "Three upgrading factors came together. <strong>Large effect:</strong> Folate reduced NTDs by 70-80%. <strong>Dose-response:</strong> Higher folate levels correlated with lower NTD risk in a clear gradient. <strong>Confounding direction:</strong> Women who take supplements tend to be healthier‚Äîwhich would make folate look beneficial even if it weren't. But folate's effect persisted after adjusting for socioeconomic factors. When an effect survives adjustment for confounders that should bias toward it, the effect is likely real. The MRC RCT eventually confirmed 72% reduction‚Äîthe observational data had been right."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Scenario: la domanda dose-risposta",
        xp: 25,
        scenario: "A series of cohort studies shows alcohol consumption and liver cirrhosis. Results: 1-2 drinks/day (RR 1.2), 3-4 drinks/day (RR 2.1), 5-6 drinks/day (RR 4.5), 7+ drinks/day (RR 9.3). The gradient is consistent across studies and populations.",
        question: "Does this dose-response pattern support upgrading?",
        options: [
          { letter: "A", text: "No, tutti gli effetti provengono da studi osservazionali", correct: false },
          { letter: "B", text: "Yes‚Äîa consistent dose-response gradient across studies suggests causation", correct: true },
          { letter: "C", text: "Only if RR exceeds 2 at all dose levels", correct: false },
          { letter: "D", text: "Only if confounders show the same gradient", correct: false }
        ],
        feedback: {
          correct: "Esatto! Un chiaro gradiente dose-risposta (1,2 ‚Üí 2,1 ‚Üí 4,5 ‚Üí 9,3) √® difficile da spiegare confondendo. Un confonditore dovrebbe monitorare perfettamente il consumo di alcol a tutti i livelli nelle diverse popolazioni. Questo gradiente biologico supporta la causalit√† e giustifica l'aggiornamento.",
          incorrect: "Le relazioni dose-risposta forniscono una forte evidenza della causalit√†. Affinch√© il confondimento crei questo modello, alcuni fattori sconosciuti dovrebbero aumentare in perfetta proporzione con l‚Äôassunzione di alcol, in ogni studio e popolazione. Ci√≤ non √® plausibile: il gradiente punta alla causalit√†."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Il paradosso confondente", title: "When Bias Proves the Case",
        text: "Consideriamo l'osservazione che i caschi da motociclista riducono le morti per lesioni alla testa. I critici potrebbero obiettare: \"Forse chi porta il casco √® un guidatore pi√π cauto\". Questo √® confuso e probabilmente √® vero. I guidatori prudenti probabilmente indossano il casco pi√π spesso.",
        followup: "But here's the paradox: if cautious driving confounds the relationship, it should bias <em>toward</em> helmets looking beneficial. Cautious drivers have fewer crashes and thus fewer head injuries. If helmets still show dramatic benefit <em>despite</em> this confounding working in their favor, the true effect might be even larger. When all plausible confounders bias in one direction and the effect persists (or is opposite), causation becomes more credible. This 'all plausible confounders' reasoning is GRADE's third upgrading criterion."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîÑ", title: "Scenario: la direzione confusa",
        xp: 25,
        scenario: "Uno studio di registro mostra che una nuova tecnica chirurgica riduce le complicanze (RR 0,60). Sospetti di confusione: i pazienti pi√π sani probabilmente ricevono la nuova tecnica. I pazienti pi√π sani avrebbero comunque meno complicazioni. Questo confondimento dovrebbe influenzare i risultati verso un beneficio.",
        question: "Does this confounding pattern support or undermine causation?",
        options: [
          { letter: "A", text: "Undermines‚Äîconfounding invalidates observational studies", correct: false },
          { letter: "B", text: "Supports‚Äîif benefit persists despite confounding that favors treatment, true benefit may exist", correct: true },
          { letter: "C", text: "Neutral‚Äîwe cannot determine confounding direction", correct: false },
          { letter: "D", text: "Undermines‚Äîwe need propensity score matching", correct: false }
        ],
        feedback: {
          correct: "Correct! If healthier patients get the new technique AND the technique still shows benefit, the true benefit might be real (or even underestimated). When confounding should bias toward benefit but benefit still appears after adjustment, that's evidence for causation. GRADE upgrades when 'all plausible confounders' would bias in the observed direction.",
          incorrect: "Think about the direction: healthy patient confounding should make the new technique look good. If the technique still shows benefit after adjusting for health status, the true effect is supported. The confounding direction helps interpret the finding."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Il riepilogo dei criteri di aggiornamento",
        subtitle: "Three paths to higher certainty",
        checkpoints: [
          { day: "LARGE", event: "RR > 2 or < 0.5 (upgrade 1); RR > 5 or < 0.2 (upgrade 2)" },
          { day: "DOSE", event: "Clear gradient between exposure and outcome" },
          { day: "CONFOUND", event: "All plausible confounders would reduce observed effect" }
        ]
      }},
      { type: "story", theme: "dark", content: {
        label: "La tempesta tiroidea", title: "When 96% Survival Speaks for Itself",
        text: "Before propylthiouracil (PTU), thyroid storm had <strong>nearly 100% mortality</strong>. With PTU, mortality dropped to around <strong>4%</strong>. No RCT was ever conducted‚Äîit would have required letting patients die in the control arm.",
        followup: "This is the paradigm case for large effect upgrading. A treatment that changes survival from ~0% to ~96% doesn't need an RCT. No confounder could explain turning certain death into reliable survival. The evidence quality was upgraded to HIGH despite being entirely observational. Some effects are simply too dramatic to doubt."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚ö†Ô∏è", title: "Scenario: l'effetto moderato",
        xp: 25,
        scenario: "Uno studio di coorte mostra che un intervento sullo stile di vita riduce le malattie cardiache con RR 0,75 (riduzione relativa del 25%). Lo studio √® ampio, ben progettato e con risultati coerenti. Un collega sostiene che questo merita un aggiornamento per un effetto pi√π ampio.",
        question: "Dovresti aggiornare?",
        options: [
          { letter: "A", text: "Yes‚Äî25% reduction is clinically important", correct: false },
          { letter: "B", text: "No‚ÄîRR 0.75 is well within the range confounding can produce", correct: true },
          { letter: "C", text: "Yes‚Äîlarge sample size warrants upgrading", correct: false },
          { letter: "D", text: "Only if dose-response is also present", correct: false }
        ],
        feedback: {
          correct: "Correct! RR 0.75 is exactly the range where confounding thrives. The HRT disaster showed RR 0.50 for heart protection‚Äîentirely due to confounding. Large effect upgrading requires RR > 2 or < 0.5 (some use even stricter thresholds). Clinical importance ‚â† causal certainty.",
          incorrect: "RR 0.75 is modest and easily explained by healthy user bias, unmeasured confounders, or selection effects. HRT's observational RR of 0.50 was entirely confounded. Only effects so large that confounding is implausible (RR > 2 or < 0.5) qualify for upgrading."
        }
      }},
      { type: "checklist", theme: "dark", content: {
        title: "Upgrading Criteria Checklist",
        items: [
          "Large effect: RR > 2 or < 0.5 (very large: > 5 or < 0.2)",
          "Dose-response: Clear gradient across exposure levels",
          "Confounding: All plausible confounders would reduce the effect",
          "Upgrading is rare‚Äîmost observational evidence remains LOW",
          "Multiple upgrading factors can be applied if clearly present"
        ]
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Perch√© le prove osservazionali sul fumo e sul cancro ai polmoni hanno raggiunto un livello di certezza ALTA nonostante l'assenza di studi randomizzati?",
        options: [
          { text: "Gli studi erano metodologicamente perfetti", correct: false },
          { text: "Large effect (30x risk) + dose-response + no plausible confounders could explain it", correct: true },
          { text: "Il meccanismo biologico era ben compreso", correct: false },
          { text: "Pi√π disegni di studio concordati", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Exactly. A 30-fold risk increase is beyond what confounding can explain. The clear dose-response (more cigarettes = more cancer) added evidence. And no unmeasured confounder has ever been found that could explain the effect. All three upgrading criteria were met.",
          incorrect: "The combination was powerful: an effect so large confounding couldn't explain it, a dose-response gradient supporting causation, and the direction of any conceivable confounding wouldn't diminish the finding. All three upgrading factors pushed the evidence to HIGH certainty."
        }
      }}
    ]
  },
  {
    id: 9, title: "Putting It Together", subtitle: "Real guideline decisions", xp: 200,
    slides: [
      { type: "title", theme: "dark", content: { title: "Putting It Together", subtitle: "Applying all five domains to real guideline decisions" }},
      { type: "objectives", theme: "dark", content: {
        objectives: [
          "Apply all GRADE domains to complex real-world evidence",
          "Esercitarsi nella costruzione di sintesi delle evidenze",
          "Make defensible certainty judgments",
          "Translate certainty to recommendation strength"
        ],
        tip: "Questo modulo presenta casi completi: utilizzerai tutto ci√≤ che hai imparato."
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Caso 1: La controversia sulle statine", title: "Statine per la prevenzione primaria",
        text: "In 2016, a Lancet review claimed statins for primary prevention were supported by <strong>'overwhelming evidence.'</strong> The meta-analysis showed 25% relative reduction in major vascular events. Industry-funded trials dominated. Patient advocates and independent researchers disagreed vehemently.",
        followup: "Let's assess this systematically. <strong>Risk of bias:</strong> Most trials industry-funded with concerns about selective reporting. <strong>Inconsistency:</strong> Effects varied by baseline risk‚Äîbenefit clear in high-risk, uncertain in low-risk. <strong>Indirectness:</strong> Many trials included patients with existing disease (secondary prevention). <strong>Imprecision:</strong> For low-risk primary prevention, confidence intervals crossed clinical thresholds. <strong>Publication bias:</strong> Industry sponsorship raised concerns about selective publication."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíä", title: "Scenario: valutazione dell'evidenza delle statine",
        xp: 30,
        scenario: "For statins in LOW-RISK primary prevention (10-year CVD risk <10%), you have: industry-funded RCTs, some risk of bias concerns, heterogeneous results by risk level, outcomes measured may include secondary prevention patients, and modest absolute benefits (NNT ~200-500 to prevent one event over 5 years).",
        question: "Quale valutazione di certezza √® pi√π appropriata per il CV riduzione degli eventi in questa popolazione?",
        options: [
          { letter: "A", text: "ALTO: la meta-analisi √® ampia e mostra un beneficio significativo", correct: false },
          { letter: "B", text: "MODERATE‚Äîdowngrade one level for indirectness (mixed populations)", correct: false },
          { letter: "C", text: "BASSO: downgrade per indirettezza E imprecisione per questa popolazione specifica", correct: true },
          { letter: "D", text: "VERY LOW‚Äîmultiple serious concerns across domains", correct: false }
        ],
        feedback: {
          correct: "Correct! For low-risk primary prevention specifically: indirectness (trials mixed with higher-risk patients) and imprecision (modest absolute benefits, NNT 200-500) both warrant downgrading. The certainty differs by population‚Äîwhat's HIGH for secondary prevention may be LOW for low-risk primary prevention.",
          incorrect: "La domanda riguarda specificamente la prevenzione primaria a BASSO RISCHIO. La meta-analisi complessiva include popolazioni a rischio pi√π elevato in cui il beneficio √® pi√π chiaro. Per la popolazione specifica in questione si applicano sia l‚Äôindirettezza che l‚Äôimprecisione. GRADE √® specifico per la popolazione."
        }
      }},
      { type: "story", theme: "dark", content: {
        label: "Caso 2: La saga dell'idrossiclorochina", title: "COVID-19 e certezza prematura",
        text: "In March 2020, a French study of <strong>36 patients</strong> claimed hydroxychloroquine cleared COVID-19 viral load. The study was open-label, non-randomized, with selective exclusion of patients who died or went to ICU. Despite this, world leaders promoted it and millions of doses were prescribed.",
        followup: "Systematic GRADE assessment would have revealed: <strong>Risk of bias:</strong> CRITICAL (non-randomized, open-label, selective exclusion). <strong>Imprecision:</strong> SERIOUS (36 patients, 6 in treatment arm). <strong>Indirectness:</strong> SERIOUS (viral load, not clinical outcomes). Certainty: <strong>VERY LOW</strong>. Subsequent RCTs (RECOVERY, WHO Solidarity) showed no benefit. The pandemic revealed what happens when certainty assessment is bypassed."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü¶†", title: "Scenario: valutazione delle prove pandemiche",
        xp: 30,
        scenario: "Emerge un nuovo virus respiratorio. Uno studio monocentrico su 80 pazienti (non randomizzato, in aperto) mostra che un farmaco riadattato riduce i ricoveri in terapia intensiva dal 25% al ‚Äã‚Äã12%. I risultati sono promossi come \"promettenti\" e generano un'enorme domanda da parte del pubblico.",
        question: "Come dovrebbero essere valutate e comunicate queste prove?",
        options: [
          { letter: "A", text: "MODERATO: la dimensione dell'effetto √® ampia e clinicamente significativa", correct: false },
          { letter: "B", text: "BASSO: studio osservazionale con gravi limitazioni", correct: false },
          { letter: "C", text: "VERY LOW‚Äîcritical risk of bias, serious imprecision; communicate uncertainty clearly", correct: true },
          { letter: "D", text: "Cannot rate‚Äîmore studies needed before any assessment", correct: false }
        ],
        feedback: {
          correct: "Correct! Non-randomized, open-label, single-center, n=80: VERY LOW certainty. The effect might be real, might be selection bias, might be confounding. Communicating this uncertainty‚Äînot dismissing the evidence, but properly contextualizing it‚Äîis essential for informed decision-making.",
          incorrect: "Questo scenario rispecchia l‚Äôidrossiclorochina. Il rischio critico di bias (non randomizzato, in aperto) pi√π grave imprecisione (80 pazienti) fornisce una certezza MOLTO BASSA. Ci√≤ non significa \"ignorarlo\", significa comunicare la profonda incertezza in attesa di prove migliori."
        }
      }},
      { type: "story", theme: "green-bg", content: {
        label: "Case 3: The Insulin Pump Victory", title: "When Certainty Builds Slowly",
        text: "L'infusione sottocutanea continua di insulina (terapia con pompa) per il diabete di tipo 1 ha accumulato prove nel corso di decenni. Le prime prove erano piccole. I risultati sono stati vari. Nessun singolo studio √® stato definitivo. Ma col tempo, il mosaico si √® ricomposto.",
        followup: "By 2010, meta-analyses showed: consistent HbA1c improvement (~0.3%), reduced severe hypoglycemia, improved quality of life. <strong>Risk of bias:</strong> Some concerns but improving over time. <strong>Inconsistency:</strong> Low for HbA1c, moderate for hypoglycemia (likely explainable by patient selection). <strong>Indirectness:</strong> None‚Äîdirect outcomes in target population. <strong>Imprecision:</strong> Resolved with cumulative trials. <strong>Publication bias:</strong> Low concern with trials in multiple settings. Final rating: <strong>MODERATE to HIGH</strong> for HbA1c improvement, with appropriate nuance for other outcomes."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìã", title: "Scenario: l'evoluzione dell'Evidence Base",
        xp: 25,
        scenario: "You're updating a guideline. Five years ago, certainty was LOW for a treatment. Since then: 3 new large RCTs with low risk of bias, consistent results (I¬≤=18%), direct population and outcomes, total events now exceed OIS, no evidence of publication bias.",
        question: "What certainty rating is now appropriate?",
        options: [
          { letter: "A", text: "Remains LOW‚Äîinitial rating shouldn't change dramatically", correct: false },
          { letter: "B", text: "MODERATE‚Äînew evidence improves but doesn't transform certainty", correct: false },
          { letter: "C", text: "HIGH‚Äînew RCTs with no serious concerns across domains", correct: true },
          { letter: "D", text: "Requires independent replication before upgrading", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE ratings should evolve as evidence evolves. Starting HIGH (RCTs), no downgrading needed: low risk of bias, consistent (I¬≤=18%), direct outcomes, adequate precision (exceeds OIS), no publication bias concern. The evidence now supports HIGH certainty.",
          incorrect: "GRADE √® una struttura vivente. Man mano che le prove si accumulano e affrontano preoccupazioni precedenti, la certezza dovrebbe essere rivalutata. Tre ampi studi randomizzati a basso bias con risultati coerenti che riguardano tutti i domini possono assolutamente aumentare la certezza da BASSO ad ALTO."
        }
      }},
      { type: "story", theme: "red-bg", content: {
        label: "Case 4: The Arthroscopy Lesson Revisited", title: "When Guidelines Persist Despite Evidence",
        text: "Nel 2008, due studi randomizzati di chirurgia simulata avevano dimostrato che l'artroscopia del ginocchio per l'osteoartrosi non era migliore del placebo. Le prove erano di ALTA certezza: studi randomizzati ben progettati, risultati coerenti, esiti diretti. Eppure le linee guida hanno impiegato anni per cambiare, e la procedura √® continuata.",
        followup: "This reveals GRADE's limitation: certainty ratings inform decisions but don't make them. Surgeons argued: 'My patients improve.' Patients wanted the procedure. Systems had invested in it. A HIGH certainty of 'no benefit' should have ended the practice‚Äîbut implementation requires more than evidence rating. GRADE tells us what the evidence says; behavior change requires understanding why evidence gets ignored."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üî¨", title: "Scenario: il divario tra prove e pratica",
        xp: 25,
        scenario: "Il vostro panel di linee guida valuta le prove come ALTA certezza che una procedura comune non √® migliore del placebo. La procedura √® redditizia, ampiamente eseguita e i pazienti riferiscono di essere soddisfatti. I membri del panel non sono d'accordo sulla forza della raccomandazione.",
        question: "What recommendation strength is appropriate given HIGH certainty of no benefit?",
        options: [
          { letter: "A", text: "Strong recommendation AGAINST‚Äîhigh certainty of no benefit demands strong action", correct: true },
          { letter: "B", text: "Conditional recommendation against‚Äîpatient preferences matter", correct: false },
          { letter: "C", text: "No recommendation‚Äîpractice patterns should determine guidelines", correct: false },
          { letter: "D", text: "Conditional recommendation for‚Äîpatients report benefit", correct: false }
        ],
        feedback: {
          correct: "Correct! HIGH certainty that a procedure provides no benefit over placebo justifies a STRONG recommendation against. Patient-reported benefit in unblinded settings is placebo effect. Resource use for ineffective treatments has opportunity costs. High certainty + unfavorable balance = strong recommendation.",
          incorrect: "Quando la certezza √® ELEVATA e il bilancio √® chiaramente sfavorevole (nessun beneficio, rischi chirurgici, costi), GRADE supporta una raccomandazione forte. La soddisfazione del paziente con il placebo non giustifica l'uso continuato di procedure invasive. Evidenze forti dovrebbero guidare raccomandazioni forti."
        }
      }},
      { type: "concept", theme: "dark", content: {
        title: "Dalla certezza alle raccomandazioni",
        subtitle: "La qualit√† delle prove √® solo una parte dell'equazione",
        text: "GRADE separates certainty of evidence from strength of recommendations. A recommendation considers:<br><br>‚Ä¢ Certainty of evidence<br>‚Ä¢ Balance of benefits vs. harms<br>‚Ä¢ Patient values and preferences<br>‚Ä¢ Resource use and feasibility",
        highlight: "Even LOW certainty evidence can support a STRONG recommendation (e.g., parachutes) if benefits clearly outweigh harms."
      }},
      { type: "story", theme: "dark", content: {
        label: "Caso 5: La soglia trasfusionale", title: "When Less Is More",
        text: "For decades, blood transfusion thresholds were set at hemoglobin <10 g/dL‚Äîthe '10/30 rule.' The practice seemed logical: more blood should be better for anemic patients. Then came the RCTs.",
        followup: "The TRICC trial (1999) and subsequent studies showed <strong>restrictive transfusion (Hb <7 g/dL)</strong> was as safe or safer than liberal transfusion in most patients. The evidence accumulated: <strong>Risk of bias:</strong> Low in major trials. <strong>Inconsistency:</strong> Low across settings. <strong>Indirectness:</strong> Some subgroups less studied. <strong>Imprecision:</strong> Resolved with multiple trials. <strong>Publication bias:</strong> Unlikely given consistent direction. Certainty: <strong>MODERATE to HIGH</strong> for most populations. Guidelines changed. A practice that had seemed obviously beneficial was actually harmful."
      }},
      { type: "decision", theme: "dark", content: {
        icon: "ü©∏", title: "Scenario: La restrizione Strategia",
        xp: 25,
        scenario: "Molti studi randomizzati mostrano che la trasfusione di sangue restrittiva √® sicura quanto la trasfusione liberale, con una mortalit√† inferiore in alcuni sottogruppi. Tuttavia, per i pazienti con sindrome coronarica acuta, esiste solo un piccolo studio randomizzato con ampi intervalli di confidenza che superano soglie clinicamente importanti.",
        question: "How should certainty differ between general hospital patients and ACS patients?",
        options: [
          { letter: "A", text: "Stessa certezza: l'evidenza complessiva si applica a tutti i pazienti", correct: false },
          { letter: "B", text: "Inferiore per le ACS: l'imprecisione e l'indirettezza richiedono una valutazione separata", correct: true },
          { letter: "C", text: "Pi√π alto per l'ACS: hanno pi√π da perdere a causa delle complicazioni trasfusionali", correct: false },
          { letter: "D", text: "Non √® possibile valutare l'ACS: prove insufficienti per qualsiasi conclusione", correct: false }
        ],
        feedback: {
          correct: "Esatto! I pazienti con SCA hanno ragioni biologiche per risposte diverse (domanda di ossigeno del miocardio). Un piccolo RCT impreciso in questa popolazione significa che l'indirettazza (estrapolazione da pazienti generali) o l'imprecisione (evidenza diretta di ACS) giustificano entrambe una certezza inferiore. GRADE √® specifico per la popolazione.",
          incorrect: "GRADE richiede la valutazione della certezza per ciascuna popolazione specifica. I pazienti con SCA possono rispondere in modo diverso rispetto ai pazienti ospedalieri. Un piccolo studio impreciso condotto direttamente su pazienti con ACS non fornisce la stessa certezza di una pi√π ampia base di prove per altre popolazioni."
        }
      }},
      { type: "quiz", theme: "dark", content: {
        question: "Qual √® la lezione pi√π importante dall'esperienza del COVID-19 con l'idrossiclorochina?",
        options: [
          { text: "Gli studi osservazionali sono sempre inaffidabili", correct: false },
          { text: "Proper GRADE assessment should precede clinical adoption and policy", correct: true },
          { text: "Repurposed drugs don't work for new diseases", correct: false },
          { text: "I media non dovrebbero riportare informazioni mediche studia", correct: false }
        ],
        xp: 20,
        feedback: {
          correct: "Esattamente. Uno studio in aperto, non randomizzato, su 36 pazienti con esclusioni selettive aveva una certezza MOLTO BASSA in base a qualsiasi valutazione GRADE. Una valutazione sistematica della certezza prima dell'adozione avrebbe impedito un uso diffuso di un trattamento inefficace e avrebbe mantenuto la fiducia del pubblico.",
          incorrect: "La lezione non √® che i piccoli studi siano inutili, ma che necessitano di un'adeguata valutazione della certezza. Una rigorosa valutazione GRADO avrebbe etichettato immediatamente questa certezza MOLTO BASSA. La valutazione sistematica deve precedere l'adozione clinica, soprattutto durante le crisi quando la pressione √® massima."
        }
      }}
    ]
  },
  {
    id: 10, title: "Final Assessment", subtitle: "Metti alla prova la tua padronanza", xp: 250,
    slides: [
      { type: "title", theme: "dark", content: { title: "Final Assessment", subtitle: "Demonstrate your mastery of GRADE certainty assessment" }},
      { type: "concept", theme: "dark", content: {
        title: "La sfida finale",
        subtitle: "Apply everything you've learned",
        text: "Questo modulo presenta scenari complessi che richiedono una valutazione GRADE integrata. Dovrai considerare pi√π domini contemporaneamente ed esprimere giudizi sfumati.",
        highlight: "Punta a una precisione dell'80% per guadagnare il badge GRADE Master!"
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìä", title: "Challenge 1: The New Cancer Drug",
        xp: 35,
        scenario: "A new cancer drug shows median survival improvement from 11 to 14 months in a single industry-funded RCT (n=600). Primary outcome was changed mid-trial from overall survival to progression-free survival. Three of seven pre-specified secondary outcomes were not reported. The survival benefit was a post-hoc analysis.",
        question: "What certainty rating is appropriate for overall survival benefit?",
        options: [
          { letter: "A", text: "HIGH‚ÄîRCT showing survival benefit", correct: false },
          { letter: "B", text: "MODERATE‚Äîsingle trial but clinically meaningful", correct: false },
          { letter: "C", text: "LOW‚Äîdowngrade for risk of bias (outcome switching, selective reporting)", correct: true },
          { letter: "D", text: "VERY LOW‚Äîmultiple serious concerns", correct: false }
        ],
        feedback: {
          correct: "Correct! Key risk of bias concerns: (1) primary outcome changed mid-trial, (2) unreported secondary outcomes, (3) survival benefit was post-hoc. Each suggests selective reporting. Starting HIGH, downgrade one or two levels for serious risk of bias. Industry funding adds concern but isn't sufficient alone for downgrading.",
          incorrect: "The trial shows classic selective reporting: changing primary endpoint, hiding unfavorable secondary outcomes, promoting post-hoc survival analysis. These risk of bias concerns require downgrading even when the finding itself is statistically significant."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üîç", title: "Sfida 2: Il puzzle della meta-analisi",
        xp: 35,
        scenario: "A meta-analysis of 20 RCTs (n=15,000) shows significant mortality reduction (RR 0.85, 95% CI 0.76-0.95). However: I¬≤=68%, prediction interval 0.62-1.15, funnel plot shows slight asymmetry, 4 trials registered but never published.",
        question: "Which domains require downgrading and by how much?",
        options: [
          { letter: "A", text: "Inconsistency (‚àí1), publication bias (‚àí1): HIGH ‚Üí LOW", correct: true },
          { letter: "B", text: "Imprecision only (‚àí1): HIGH ‚Üí MODERATE", correct: false },
          { letter: "C", text: "Inconsistency (‚àí2): HIGH ‚Üí LOW", correct: false },
          { letter: "D", text: "Publication bias only (‚àí1): HIGH ‚Üí MODERATE", correct: false }
        ],
        feedback: {
          correct: "Correct! Inconsistency: I¬≤=68% with prediction interval crossing 1.0 (could show harm) warrants one downgrade. Publication bias: 4 registered but unpublished trials plus funnel asymmetry warrants one downgrade. Two domains = two downgrades = HIGH ‚Üí LOW.",
          incorrect: "L'intervallo di previsione (0,62-1,15) incrocia 1,0: il successivo lo studio potrebbe mostrare danni. Questa √® una grave incoerenza. L'asimmetria del funnel pi√π 4 studi registrati non pubblicati sono la prova diretta di bias di pubblicazione. Entrambi gli ambiti meritano un downgrade."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üíâ", title: "Sfida 3: L'efficacia del vaccino",
        xp: 35,
        scenario: "A vaccine trial (n=40,000) shows 95% efficacy against symptomatic disease (RR 0.05, 95% CI 0.03-0.08). Low risk of bias, consistent subgroup results, direct outcome. However, follow-up is only 3 months, and durability of protection is unknown.",
        question: "How should certainty be rated for short-term vs. long-term efficacy?",
        options: [
          { letter: "A", text: "HIGH for both‚Äîlarge, well-conducted trial", correct: false },
          { letter: "B", text: "HIGH for short-term; VERY LOW for long-term (no data)", correct: false },
          { letter: "C", text: "HIGH for short-term efficacy; LOW for 12-month efficacy (indirect/imprecise)", correct: true },
          { letter: "D", text: "MODERATE for both‚Äîduration uncertainty affects all conclusions", correct: false }
        ],
        feedback: {
          correct: "Correct! Short-term efficacy: large RCT, low bias, precise, direct = HIGH. Long-term efficacy: either indirect (extrapolating from 3 months) or imprecise (no data). GRADE is outcome-specific‚Äîdifferent time horizons may have different certainty ratings.",
          incorrect: "GRADE valuta la certezza per risultati specifici. I dati a tre mesi supportano direttamente l‚Äôefficacia a tre mesi (ALTA). L‚Äôefficacia a dodici mesi richiede un‚Äôestrapolazione (indiretta) o non dispone di dati diretti (imprecisione). Lo stesso studio supporta certezze diverse per domande diverse."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "‚öñÔ∏è", title: "Sfida 4: L'aggiornamento osservativo",
        xp: 35,
        scenario: "Cohort studies show a procedure reduces mortality from 95% to 15% (RR 0.16). No RCTs exist because the natural history (95% death) makes randomization unethical. Dose-response is present: earlier intervention shows better outcomes. All plausible confounders would make patients receiving intervention sicker (selection of more severe cases).",
        question: "Questa evidenza osservativa dovrebbe essere aggiornata e a quale livello?",
        options: [
          { letter: "A", text: "No upgrade‚Äîobservational evidence stays LOW", correct: false },
          { letter: "B", text: "Upgrade to MODERATE‚Äîone upgrading factor (large effect)", correct: false },
          { letter: "C", text: "Upgrade to HIGH‚Äîall three upgrading factors clearly present", correct: true },
          { letter: "D", text: "Upgrade to MODERATE‚Äîobservational can never reach HIGH", correct: false }
        ],
        feedback: {
          correct: "Correct! All three upgrading factors: (1) Large effect‚ÄîRR 0.16 (84% relative reduction from 95% to 15%). (2) Dose-response‚Äîearlier = better. (3) Confounding direction‚Äîsicker patients receive intervention, which would bias AGAINST benefit if anything. Multiple upgrading factors can raise observational evidence to HIGH.",
          incorrect: "Questo soddisfa tutti e tre i criteri di aggiornamento. La dimensione dell‚Äôeffetto (RR 0,16) √® molto ampia: mortalit√† dal 95% al ‚Äã‚Äã15%. Presente la risposta alla dose. E il confondimento √® OPPOSTO all'effetto osservato (i pazienti pi√π malati ricevono la procedura). L'evidenza osservativa pu√≤ raggiungere un livello di certezza ELEVATO quando tutti i criteri sono chiaramente soddisfatti."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üéØ", title: "Sfida 5: il risultato composito",
        xp: 35,
        scenario: "An RCT shows significant reduction in 'major adverse cardiovascular events' (MACE: CV death, MI, stroke). However, decomposition reveals: CV death RR 1.02 (95% CI 0.85-1.22), MI RR 0.82 (0.72-0.94), Stroke RR 0.95 (0.80-1.13). The MACE benefit is driven entirely by MI.",
        question: "How should certainty differ for MACE vs. individual components?",
        options: [
          { letter: "A", text: "Same certainty‚ÄîMACE is the primary outcome", correct: false },
          { letter: "B", text: "MACE HIGH; CV death/stroke may be rated MODERATE (imprecision)", correct: false },
          { letter: "C", text: "MI HIGH; CV death/stroke LOW (CI includes substantial harm/benefit); MACE MODERATE (driven by MI)", correct: true },
          { letter: "D", text: "Tutti i componenti ALTO: provengono dallo stesso RCT ben condotto", correct: false }
        ],
        feedback: {
          correct: "Correct! GRADE is outcome-specific. MI evidence is precise (0.72-0.94 excludes 1.0). CV death and stroke CIs are wide and cross 1.0‚Äîwe can't exclude no effect or harm. MACE driven entirely by MI means the composite obscures component-specific uncertainty. Different outcomes warrant different ratings even from the same trial.",
          incorrect: "I risultati compositi possono mascherare l'incertezza specifica del componente. L‚ÄôRCT mostra una chiara riduzione dell‚ÄôIM ma incertezza sulla morte CV e sull‚Äôictus. I pazienti e i medici devono sapere se il farmaco previene i decessi o solo eventi non fatali. GRADE valuta ciascun risultato separatamente."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üìâ", title: "Sfida 6: Il risultato fragile",
        xp: 35,
        scenario: "A meta-analysis of 5 small RCTs (total n=800, 48 events) shows statistically significant mortality benefit (RR 0.55, 95% CI 0.32-0.95, p=0.03). The fragility index is 2. A single large RCT (n=3,000) is underway.",
        question: "What certainty rating is appropriate while awaiting the large trial?",
        options: [
          { letter: "A", text: "HIGH‚Äîstatistically significant benefit from RCTs", correct: false },
          { letter: "B", text: "MODERATE‚Äîsome imprecision but consistent direction", correct: false },
          { letter: "C", text: "LOW‚Äîserious imprecision (48 events, fragility index 2, below OIS)", correct: true },
          { letter: "D", text: "Non posso valutare: attendere lo studio pi√π ampio", correct: false }
        ],
        feedback: {
          correct: "Correct! 48 events is far below typical OIS (200-400 for mortality). Fragility index of 2 means 2 different outcomes would flip the result. The CI is wide (0.32-0.95). This is classic imprecision requiring downgrade. We can make provisional conclusions while acknowledging the large trial may change everything.",
          incorrect: "Statistical significance doesn't guarantee precision. The fragility index of 2 means the 'significant' result is extremely unstable. 48 events is grossly underpowered for mortality conclusions. GRADE requires downgrading for imprecision‚Äîwe should be honest about uncertainty while awaiting better data."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üß¨", title: "Sfida 7: Il risultato surrogato",
        xp: 35,
        scenario: "A drug dramatically improves bone mineral density (+8% annually). Observational data suggest each 1% density improvement correlates with 5% fracture reduction. No fracture outcome trials have been conducted. The drug class has previously produced agents where density improved but fractures increased.",
        question: "What certainty applies to fracture prevention?",
        options: [
          { letter: "A", text: "MODERATE‚Äîstrong surrogate relationship", correct: false },
          { letter: "B", text: "LOW‚Äîindirect evidence, but plausible mechanism", correct: false },
          { letter: "C", text: "VERY LOW‚Äîserious indirectness (surrogate only) PLUS known discordance in drug class", correct: true },
          { letter: "D", text: "Cannot rate until fracture trials complete", correct: false }
        ],
        feedback: {
          correct: "Correct! Surrogate outcomes require downgrading for indirectness. But here there's added concern: the drug class has precedent for density-fracture discordance (like sodium fluoride). This history of surrogate-outcome discordance in the same class warrants serious downgrading. Starting LOW (observational), downgrade further for known class discordance.",
          incorrect: "Il caso del fluoruro di sodio (densit√† aumentata, fratture) √® direttamente rilevante: stessa classe di farmaci con nota discordanza dei risultati surrogati. Quando una classe di farmaci ha dimostrato che il surrogato pu√≤ muoversi in modo opposto ai risultati, i dati surrogati di un nuovo farmaco in quella classe sono profondamente incerti."
        }
      }},
      { type: "decision", theme: "dark", content: {
        icon: "üè•", title: "Sfida 8: Evidenza a livello di sistema",
        xp: 35,
        scenario: "Un RCT a grappolo a gradini mostra che un protocollo ospedaliero riduce la mortalit√† a 30 giorni (OR 0,75, IC 95% 0,62-0,91). Hanno partecipato venti ospedali. Tuttavia, l'intervento √® stato implementato in modo diverso nei diversi centri, i risultati sono stati valutati in cieco e 5 ospedali si sono ritirati a met√† della sperimentazione.",
        question: "Quali domini GRADE sono interessati da queste caratteristiche metodologiche?",
        options: [
          { letter: "A", text: "Risk of bias only‚Äîother domains unaffected", correct: false },
          { letter: "B", text: "Risk of bias (unblinded, attrition) + inconsistency (implementation variation)", correct: true },
          { letter: "C", text: "Imprecision only‚Äî20 hospitals may be insufficient", correct: false },
          { letter: "D", text: "Indirectness‚Äîcluster trials don't apply to individual patients", correct: false }
        ],
        feedback: {
          correct: "Correct! Risk of bias: unblinded outcome assessment introduces detection bias; 5 hospital withdrawals are attrition bias. Inconsistency: variable implementation across sites may cause heterogeneity (different hospitals implementing different versions). Both domains warrant scrutiny.",
          incorrect: "La valutazione in cieco e l'attrito (5 ospedali che abbandonano) sono classici rischi di bias. L'implementazione variabile √® un problema di incoerenza: se gli ospedali implementano in modo diverso, l'intervento non √® uniforme e i risultati possono variare in base alla fedelt√† dell'implementazione."
        }
      }},
      { type: "stats", theme: "dark", content: {
        title: "GRADE in Numbers",
        stats: [
          { value: "4", label: "Certainty levels" },
          { value: "5", label: "Downgrading domains" },
          { value: "3", label: "Upgrading factors" },
          { value: "‚àû", label: "Lives protected by rigorous assessment" }
        ],
        caption: "Systematic certainty assessment protects patients from overconfident medicine."
      }},
      { type: "refrain", theme: "black", content: { text: "La certezza non riguarda quante prove esistono. Dipende da quanto dovremmo fidarci." }},
      { type: "quiz", theme: "dark", content: {
        question: "Qual √® l'intuizione fondamentale fornita da GRADE per la medicina basata sull'evidenza?",
        options: [
          { text: "Studi pi√π ampi sono sempre migliori", correct: false },
          { text: "Gli studi randomizzati sono gli unici validi prove", correct: false },
          { text: "La certezza deve essere valutata sistematicamente, con ragionamenti trasparenti per ciascun dominio", correct: true },
          { text: "Meta-analyses provide definitive answers", correct: false }
        ],
        xp: 25,
        feedback: {
          correct: "Exactly. GRADE transforms implicit judgments into explicit, transparent assessments. By systematically considering risk of bias, inconsistency, indirectness, imprecision, and publication bias‚Äîand documenting reasoning‚ÄîGRADE makes certainty assessment reproducible and debatable. This transparency is its core contribution.",
          incorrect: "Il contributo fondamentale di GRADE √® la trasparenza strutturata. Piuttosto che vaghi marchi di qualit√†, richiede una valutazione sistematica di ambiti specifici con un ragionamento esplicito. Ci√≤ rende i giudizi certi riproducibili, discutibili e migliorabili man mano che le prove si accumulano."
        }
      }}
    ]
  }
];

// ===== NAVIGATION STATE =====
let currentModule = 0;
let currentSlide = 0;
let consecutiveCorrect = gameState.consecutiveCorrect || 0;

// ===== SAVE/LOAD =====
function saveGame() {
  safeSetStorage('gradeGame_v1', gameState);
}

function resetProgress() {
  if (confirm('Reset all progress and achievements?')) {
    gameState = { ...DEFAULT_STATE, answeredQuestions: {}, badges: [], completedModules: [] };
    saveGame();
    currentModule = 0;
    currentSlide = 0;
    renderAll();
  }
}

// ===== COURSE PROGRESS =====
function updateCourseProgress() {
  const totalModules = MODULES.length;
  const completedCount = gameState.completedModules.length;
  const pct = Math.round((completedCount / totalModules) * 100);
  const fillEl = document.getElementById('courseProgressFill');
  const pctEl = document.getElementById('courseProgressPct');
  if (fillEl) fillEl.style.width = pct + '%';
  if (pctEl) pctEl.textContent = pct + '%';
}

// ===== XP & LEVELING =====
function addXP(amount) {
  gameState.xp += amount;
  checkLevelUp();
  saveGame();
  updateStatsDisplay();
  showXPPopup(amount);
}

function checkLevelUp() {
  for (let i = LEVELS.length - 1; i >= 0; i--) {
    if (gameState.xp >= LEVELS[i].xp && gameState.level < LEVELS[i].level) {
      gameState.level = LEVELS[i].level;
      showLevelUp(LEVELS[i]);
      break;
    }
  }
}

function showXPPopup(amount) {
  const popup = document.getElementById('xpPopup');
  document.getElementById('xpAmount').textContent = `+${amount}`;
  popup.classList.add('show');
  setTimeout(() => popup.classList.remove('show'), 1500);
}

function showLevelUp(levelData) {
  triggerConfetti();
}

// ===== BADGES =====
function awardBadge(badgeId) {
  if (gameState.badges.includes(badgeId)) return;
  gameState.badges.push(badgeId);
  saveGame();
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
  updateBadges();
}

function showBadgeDetails(badgeId) {
  const badge = BADGES.find(b => b.id === badgeId);
  if (badge) showBadgeModal(badge);
}

let _badgeModalTrapHandler = null;

function showBadgeModal(badge) {
  const modal = document.getElementById('badgeModal');
  document.getElementById('badgeModalIcon').textContent = badge.icon;
  document.getElementById('badgeModalTitle').textContent = badge.name;
  document.getElementById('badgeModalDesc').textContent = badge.desc;
  modal.classList.add('show');
  triggerConfetti();

  // Focus trap for accessibility
  const focusableElements = modal.querySelectorAll('button, [tabindex]:not([tabindex="-1"])');
  if (focusableElements.length > 0) {
    focusableElements[0].focus();
  }

  // Remove any previous handler before adding a new one
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
  }

  _badgeModalTrapHandler = function(e) {
    if (e.key === 'Escape') {
      closeBadgeModal();
      return;
    }
    if (e.key === 'Tab') {
      const firstFocusable = focusableElements[0];
      const lastFocusable = focusableElements[focusableElements.length - 1];
      if (e.shiftKey && document.activeElement === firstFocusable) {
        e.preventDefault();
        lastFocusable.focus();
      } else if (!e.shiftKey && document.activeElement === lastFocusable) {
        e.preventDefault();
        firstFocusable.focus();
      }
    }
  };
  modal.addEventListener('keydown', _badgeModalTrapHandler);
}

function closeBadgeModal() {
  const modal = document.getElementById('badgeModal');
  if (_badgeModalTrapHandler) {
    modal.removeEventListener('keydown', _badgeModalTrapHandler);
    _badgeModalTrapHandler = null;
  }
  modal.classList.remove('show');
}

// ===== STREAK =====
function updateStreak() {
  const today = new Date().toDateString();
  if (gameState.lastActive !== today) {
    const yesterday = new Date(Date.now() - 86400000).toDateString();
    if (gameState.lastActive === yesterday) {
      gameState.streak++;
      if (gameState.streak >= 3) awardBadge('streak_3');
      if (gameState.streak >= 7) awardBadge('streak_7');
    } else if (gameState.lastActive) {
      gameState.streak = 1;
    } else {
      gameState.streak = 1;
    }
    gameState.lastActive = today;
    saveGame();
  }
}

// ===== CONFETTI =====
function triggerConfetti() {
  if (window.matchMedia('(prefers-reduced-motion: reduce)').matches) return;
  const container = document.getElementById('confettiContainer');
  const colors = ['#D4AF37', '#22c55e', '#3b82f6', '#f59e0b', '#ef4444', '#7c3aed'];
  for (let i = 0; i < 50; i++) {
    const confetti = document.createElement('div');
    confetti.className = 'confetti';
    confetti.style.left = Math.random() * 100 + '%';
    confetti.style.background = colors[Math.floor(Math.random() * colors.length)];
    confetti.style.animationDelay = Math.random() * 0.5 + 's';
    container.appendChild(confetti);
    setTimeout(() => confetti.remove(), 3500);
  }
}

// ===== COMBO =====
function updateComboDisplay() {
  const comboEl = document.getElementById('comboDisplay');
  const countEl = document.getElementById('comboCount');
  if (consecutiveCorrect >= 2) {
    countEl.textContent = consecutiveCorrect;
    comboEl.classList.add('show');
  } else {
    comboEl.classList.remove('show');
  }
}

// ===== MOBILE SIDEBAR =====
function toggleSidebar() {
  document.querySelector('.sidebar').classList.toggle('open');
  document.getElementById('sidebarOverlay').classList.toggle('show');
  var btn = document.querySelector('.sidebar-toggle, .hamburger, .mobile-menu-btn'); if (btn) btn.setAttribute('aria-expanded', btn.getAttribute('aria-expanded') === 'true' ? 'false' : 'true');
}

// ===== RENDER =====
function renderAll() {
  updateStreak();
  renderSidebar();
  renderSlides();
  updateStatsDisplay();
  updateBadges();
  updateCourseProgress();
}

function updateStatsDisplay() {
  const levelData = LEVELS.find(l => l.level === gameState.level) || LEVELS[0];
  const nextLevel = LEVELS.find(l => l.level === gameState.level + 1);

  document.getElementById('levelIcon').textContent = levelData.icon;
  document.getElementById('levelTitle').textContent = levelData.title;
  document.getElementById('levelNum').textContent = gameState.level;

  const currentXP = gameState.xp - levelData.xp;
  const neededXP = nextLevel ? (nextLevel.xp - levelData.xp) : 500;
  const pct = Math.min(100, (currentXP / neededXP) * 100);

  document.getElementById('xpFill').style.width = pct + '%';
  document.getElementById('xpCurrent').textContent = currentXP;
  document.getElementById('xpNeeded').textContent = neededXP;

  document.getElementById('correctCount').textContent = gameState.correctAnswers;
  document.getElementById('decisionCount').textContent = gameState.decisionsCompleted;
  document.getElementById('gradesCount').textContent = gameState.gradesAssigned || 0;
  document.getElementById('streakCount').textContent = gameState.streak;

  const streakEl = document.getElementById('streakDisplay');
  streakEl.classList.toggle('active', gameState.streak > 0);
}

function updateBadges() {
  const grid = document.getElementById('badgesGrid');
  grid.innerHTML = BADGES.map(b => {
    const earned = gameState.badges.includes(b.id);
    return `<button class="badge-item ${earned ? 'earned' : ''}" type="button" ${earned ? `onclick="showBadgeDetails('${b.id}')"` : ''} aria-label="${b.name}: ${b.desc}" title="${b.name}: ${b.desc}" style="min-width:44px;min-height:44px">${b.icon}</button>`;
  }).join('');
}

function renderSidebar() {
  const list = document.getElementById('moduleList');
  list.innerHTML = MODULES.map((mod, i) => {
    const completed = gameState.completedModules.includes(mod.id);
    const locked = i > 0 && !gameState.completedModules.includes(MODULES[i-1].id);
    const estMins = Math.round(mod.slides.length * 1.5);
    return `
      <div class="module-item ${i === currentModule ? 'active' : ''} ${completed ? 'completed' : ''} ${locked ? 'locked' : ''}"
           onclick="${locked ? '' : `goToModule(${i})`}"
           tabindex="${locked ? -1 : 0}"
           role="button"
           aria-disabled="${locked ? 'true' : 'false'}">
        <div class="module-number">${completed ? '‚úì' : (locked ? 'üîí' : mod.id)}</div>
        <div class="module-info">
          <div class="module-title">${mod.title}</div>
          <div class="module-subtitle">${mod.subtitle}</div>
          <div class="module-xp">+${mod.xp} XP</div>
          <div class="module-time">‚è±Ô∏è ~${estMins} min</div>
        </div>
      </div>
    `;
  }).join('');
}

function renderSlides() {
  const container = document.getElementById('slidesContainer');
  container.innerHTML = MODULES.map((mod, mi) => {
    const progressPct = ((currentSlide + 1) / mod.slides.length) * 100;
    return `
    <div class="module-slides ${mi === currentModule ? 'active' : ''}" data-module="${mi}">
      <div class="slide-progress-bar" style="width: ${mi === currentModule ? progressPct : 0}%"></div>
      ${mod.slides.map((slide, si) => renderSlide(slide, si, mi)).join('')}
      <div class="slide-nav">
        <button class="nav-btn" onclick="prevSlide()" ${currentSlide === 0 ? 'disabled' : ''} aria-label="Previous slide">‚Üê</button>
        <div class="nav-center">
          <div class="slide-counter">${currentSlide + 1} / ${mod.slides.length}</div>
          <div class="progress-dots">
            ${mod.slides.map((_, i) => `<button class="progress-dot ${i === currentSlide ? 'active' : ''}" type="button" onclick="goToSlide(${i})" aria-label="Go to slide ${i + 1}" ${i === currentSlide ? 'aria-current="true"' : ''}></button>`).join('')}
          </div>
        </div>
        <button class="nav-btn" onclick="nextSlide()" aria-label="Next slide">‚Üí</button>
      </div>
      <div class="keyboard-hint" style="position:absolute;bottom:5px;left:50%;transform:translateX(-50%);font-size:0.6rem;opacity:0.4;">‚Üê ‚Üí arrows or swipe to navigate</div>
    </div>
  `;
  }).join('');
  document.getElementById('currentModule').textContent = MODULES[currentModule].title;
  updateSlideVisibility();
}

function renderSlide(slide, index, moduleIndex) {
  const theme = slide.theme || 'dark';
  let html = `<div class="slide ${theme} ${index === currentSlide ? 'active' : ''}" data-slide="${index}">`;

  switch(slide.type) {
    case 'title':
      html += `<div class="content"><h1 class="title gold animate">${slide.content.title}</h1><p class="subtitle animate delay-1">${slide.content.subtitle}</p></div>`;
      break;

    case 'objectives':
      html += `<div class="content">
        <div class="objectives-box animate">
          <div class="objectives-header">
            <div class="objectives-icon">üéØ</div>
            <div class="objectives-title">Learning Objectives</div>
          </div>
          <ul class="objectives-list">
            ${slide.content.objectives.map(obj => `<li>${obj}</li>`).join('')}
          </ul>
        </div>
        ${slide.content.tip ? `<p class="subtitle animate delay-1" style="font-size:0.85rem;max-width:600px">${slide.content.tip}</p>` : ''}
      </div>`;
      break;

    case 'story':
      html += `<div class="content">
        <article class="story-box ${slide.content.success ? 'success' : ''} animate" role="article">
          <div class="story-label">${slide.content.label}</div>
          ${slide.content.title ? `<h2 class="title gold" style="font-size:1.8rem;margin-bottom:0.75rem">${slide.content.title}</h2>` : ''}
          <p class="story-text">${slide.content.text}</p>
          ${slide.content.followup ? `<p class="story-text" style="margin-top:0.75rem;font-style:italic;opacity:0.9">${slide.content.followup}</p>` : ''}
        </article>
      </div>`;
      break;

    case 'stats':
      html += `<div class="content">
        ${slide.content.title ? `<h2 class="title gold animate">${slide.content.title}</h2>` : ''}
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        <div class="stats-grid animate delay-2">
          ${slide.content.stats.map(s => `<div class="stat-box"><div class="stat-value gold">${s.value}</div><div class="stat-label">${s.label}</div></div>`).join('')}
        </div>
        ${slide.content.caption ? `<p class="subtitle animate delay-3" style="font-size:0.85rem;margin-top:0.75rem">${slide.content.caption}</p>` : ''}
      </div>`;
      break;

    case 'refrain':
      html += `<div class="content" style="justify-content:center;height:100%"><p class="refrain animate">"${slide.content.text}"</p></div>`;
      break;

    case 'concept':
      html += `<div class="content">
        <h2 class="title ${theme === 'light' ? 'navy' : 'gold'} animate">${slide.content.title}</h2>
        ${slide.content.subtitle ? `<p class="subtitle animate delay-1">${slide.content.subtitle}</p>` : ''}
        ${slide.content.text ? `<div class="card ${theme === 'light' ? '' : 'navy-bg'} animate delay-2"><p class="card-text">${slide.content.text}</p></div>` : ''}
        ${slide.content.highlight ? `<div class="story-box warning animate delay-3"><div class="story-label">Key Insight</div><p class="story-text">${slide.content.highlight}</p></div>` : ''}
        ${slide.content.checkpoints ? `
          <div class="timeline animate delay-2" style="margin-top:0.75rem">
            ${slide.content.checkpoints.map(cp => `
              <div class="timeline-item"><div class="timeline-days">${cp.day}</div><div class="timeline-content"><div class="timeline-title">${cp.event}</div></div></div>
            `).join('')}
          </div>
        ` : ''}
      </div>`;
      break;

    case 'checklist':
      html += `<div class="content">
        <h2 class="title gold animate">${slide.content.title}</h2>
        <div class="checklist animate delay-1">
          ${slide.content.items.map(item => `
            <div class="checklist-item">
              <div class="check-icon">‚úì</div>
              <div class="checklist-text">${item}</div>
            </div>
          `).join('')}
        </div>
      </div>`;
      break;

    case 'decision':
      const did = `dec_${moduleIndex}_${index}`;
      const answered = gameState.answeredQuestions[did];
      html += `<div class="content">
        <div class="decision-tree animate">
          <div class="decision-header">
            <div class="decision-icon">${slide.content.icon}</div>
            <div class="decision-title">${slide.content.title}</div>
            <div class="decision-xp">+${slide.content.xp} XP</div>
          </div>
          <div class="decision-scenario">${slide.content.scenario}</div>
          <div class="decision-question">${slide.content.question}</div>
          <div class="decision-options">
            ${slide.content.options.map(opt => {
              const isSelected = answered === opt.letter;
              const showCorrect = answered && opt.correct;
              const showIncorrect = answered && isSelected && !opt.correct;
              return `
                <div class="decision-option ${isSelected ? 'selected' : ''} ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${answered ? 'disabled' : ''}"
                     onclick="answerDecision('${did}', '${opt.letter}', ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button"
                     aria-disabled="${answered ? 'true' : 'false'}">
                  <div class="option-letter">${opt.letter}</div>
                  <div class="option-text">${opt.text}</div>
                </div>
              `;
            }).join('')}
          </div>
          <div class="decision-feedback ${answered ? 'show' : ''} ${answered && slide.content.options.find(o => o.letter === answered)?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            <div class="feedback-title">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? '‚úì Correct!' : '‚úó Not quite'}</div>
            <div class="feedback-text">${answered && slide.content.options.find(o => o.letter === answered)?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}</div>
          </div>
        </div>
      </div>`;
      break;

    case 'quiz':
      const qid = `quiz_${moduleIndex}_${index}`;
      const qAnswered = gameState.answeredQuestions[qid];
      html += `<div class="content">
        <div class="quiz-container animate">
          <div class="quiz-question">${slide.content.question}</div>
          <div class="quiz-options">
            ${slide.content.options.map((opt, oi) => {
              const isSelected = qAnswered === oi;
              const showCorrect = qAnswered !== undefined && opt.correct;
              const showIncorrect = qAnswered !== undefined && isSelected && !opt.correct;
              return `
                <div class="quiz-option ${showCorrect ? 'correct' : ''} ${showIncorrect ? 'incorrect' : ''} ${qAnswered !== undefined ? 'disabled' : ''}"
                     onclick="answerQuiz('${qid}', ${oi}, ${opt.correct}, ${slide.content.xp})"
                     tabindex="0"
                     role="button">
                  ${opt.text}
                </div>
              `;
            }).join('')}
          </div>
          <div class="quiz-feedback ${qAnswered !== undefined ? 'show' : ''} ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? 'correct' : 'incorrect'}" role="alert" aria-live="polite">
            ${qAnswered !== undefined && slide.content.options[qAnswered]?.correct ? slide.content.feedback.correct : slide.content.feedback.incorrect}
          </div>
        </div>
      </div>`;
      break;
  }

  html += '</div>';
  return html;
}

function updateSlideVisibility() {
  const container = document.querySelector('.module-slides.active');
  if (!container) return;

  container.querySelectorAll('.slide').forEach((slide, i) => {
    slide.classList.toggle('active', i === currentSlide);
  });

  const progressBar = container.querySelector('.slide-progress-bar');
  if (progressBar) {
    const pct = ((currentSlide + 1) / MODULES[currentModule].slides.length) * 100;
    progressBar.style.width = pct + '%';
  }

  container.querySelector('.slide-counter').textContent = `${currentSlide + 1} / ${MODULES[currentModule].slides.length}`;
  container.querySelectorAll('.progress-dot').forEach((dot, i) => {
    dot.classList.toggle('active', i === currentSlide);
  });
  container.querySelector('.nav-btn').disabled = currentSlide === 0;
}

// ===== ANSWERS =====
function answerDecision(did, letter, correct, xp) {
  if (gameState.answeredQuestions[did] !== undefined) return;
  gameState.answeredQuestions[did] = letter;
  gameState.decisionsCompleted++;
  gameState.gradesAssigned = (gameState.gradesAssigned || 0) + 1;

  // Award first_grade badge on first decision
  if (gameState.decisionsCompleted === 1) awardBadge('first_grade');

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
    if (gameState.decisionsCompleted >= 15) awardBadge('decision_maker');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
  updateStatsDisplay();
}

function answerQuiz(qid, choice, correct, xp) {
  if (gameState.answeredQuestions[qid] !== undefined) return;
  gameState.answeredQuestions[qid] = choice;

  if (correct) {
    gameState.correctAnswers++;
    consecutiveCorrect++;
    addXP(xp);
    if (consecutiveCorrect >= 5) awardBadge('perfect_5');
  } else {
    consecutiveCorrect = 0;
  }
  gameState.consecutiveCorrect = consecutiveCorrect;
  saveGame();
  renderSlides();
  updateComboDisplay();
}

// ===== NAVIGATION =====
function goToModule(index) {
  if (index > 0 && !gameState.completedModules.includes(MODULES[index-1].id)) return;
  currentModule = index;
  currentSlide = 0;
  renderSlides();
  renderSidebar();
}

function goToSlide(index) {
  currentSlide = index;
  updateSlideVisibility();
}

function nextSlide() {
  const mod = MODULES[currentModule];
  if (currentSlide < mod.slides.length - 1) {
    currentSlide++;
    updateSlideVisibility();
  } else {
    completeModule();
  }
}

function prevSlide() {
  if (currentSlide > 0) {
    currentSlide--;
    updateSlideVisibility();
  }
}

function completeModule() {
  const mod = MODULES[currentModule];
  if (!gameState.completedModules.includes(mod.id)) {
    gameState.completedModules.push(mod.id);
    addXP(mod.xp);

    // Module-specific badges
    if (mod.id === 3) awardBadge('bias_hunter');
    if (mod.id === 4) awardBadge('consistency_king');
    if (mod.id === 5) awardBadge('directness_detective');
    if (mod.id === 6) awardBadge('precision_master');
    if (mod.id === 7) awardBadge('publication_sleuth');
    if (mod.id === 8) awardBadge('upgrader');
    if (mod.id === 10) awardBadge('grade_master');
    if (gameState.completedModules.length === MODULES.length) awardBadge('finisher');

    saveGame();
    triggerConfetti();
    updateCourseProgress();
  }

  if (currentModule < MODULES.length - 1) {
    goToModule(currentModule + 1);
  }
}

// ===== KEYBOARD =====
document.addEventListener('keydown', (e) => {
  const isRoleButton = e.target && e.target.getAttribute && e.target.getAttribute('role') === 'button';
  const isFormControl = e.target && e.target.closest && e.target.closest('button, a, input, textarea, select, [role="radio"], [role="option"]');
  if (isRoleButton || isFormControl) {
    if ((e.key === ' ' || e.key === 'Enter') && isRoleButton) { e.preventDefault(); e.target.click(); }
    return;
  }
  if (e.key === 'Escape') {
    closeBadgeModal();
    document.querySelector('.sidebar').classList.remove('open');
    document.getElementById('sidebarOverlay').classList.remove('show');
    return;
  }
  if (e.key === 'ArrowRight' || e.key === ' ') { e.preventDefault(); nextSlide(); }
  else if (e.key === 'ArrowLeft') { e.preventDefault(); prevSlide(); }
});

// Second keydown handler removed (first handler covers role="button" elements)

// ===== TOUCH =====
let touchStartX = 0;
document.addEventListener('touchstart', (e) => { touchStartX = e.changedTouches[0].screenX; }, { passive: true });
document.addEventListener('touchend', (e) => {
  const diff = touchStartX - e.changedTouches[0].screenX;
  if (Math.abs(diff) > 50) { diff > 0 ? nextSlide() : prevSlide(); }
}, { passive: true });

// ===== INIT =====
renderAll();
</script>
</body>
</html>
